

# EXHIBIT

1

AO 88 (Rev. 02/14) Subpoena to Appear and Testify at a Hearing or Trial in a Civil Action

UNITED STATES DISTRICT COURT  
for the  
District of Massachusetts

In re Nexium (Esomeprazole)  
Antitrust Litigation )  
 )  
 )  
 )  
 )  
 )  
 ) Civil Action No. 12-md-02409-WGY

SUBPOENA TO APPEAR AND TESTIFY  
AT A HEARING OR TRIAL IN A CIVIL ACTION

To: Keeper of Records, Rambaxy Inc.  
c/o The Prentice Hall Corporation System, Inc., 2711 Centerville Road Suite 400, Wilmington DE 19808  
(Name of person to whom this subpoena is directed)

**YOU ARE COMMANDED** to appear in the United States district court at the time, date, and place set forth below to testify at a hearing or trial in this civil action. When you arrive, you must remain at the court until the judge or a court officer allows you to leave. See **Attachments A and B for further information.**

Place: Clarkson S. Fisher Building & U.S. Courthouse  
402 East State Street  
Trenton, NJ 08608

Courtroom No.: To be determined  
Date and Time: Beginning October 22, 2014 at  
9:00 a.m. and every day thereafter until dismissed

You must also bring with you the following documents, electronically stored information, or objects (*leave blank if not applicable*):

The following provisions of Fed. R. Civ. P. 45 are attached – Rule 45(c), relating to the place of compliance; Rule 45(d), relating to your protection as a person subject to a subpoena; and Rule 45(e) and (g), relating to your duty to respond to this subpoena and the potential consequences of not doing so.

Date: \_\_\_\_\_

CLERK OF COURT

OR

*Thomas Sobol*  
Signature of Clerk or Deputy Clerk

*NY*  
Attorney's signature

The name, address, e-mail address, and telephone number of the attorney representing (*name of party*) \_\_\_\_\_  
the Direct Purchaser Class Plaintiffs \_\_\_\_\_, who issues or requests this subpoena, are:

Thomas M. Sobol, Hagens Berman Sobol Shapiro LLP  
55 Cambridge Parkway, Suite 301, Cambridge, MA 02142 tom@hbsslaw.com (617) 482-3000

Notice to the person who issues or requests this subpoena

If this subpoena commands the production of documents, electronically stored information, or tangible things before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

AO 88 (Rev. 02/14) Subpoena to Appear and Testify at a Hearing or Trial in a Civil Action (page 2)

Civil Action No. 12-md-02409-WGY

**PROOF OF SERVICE**

*(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)*

I received this subpoena for *(name of individual and title, if any)* \_\_\_\_\_  
on *(date)* \_\_\_\_\_.

I served the subpoena by delivering a copy to the named person as follows:

\_\_\_\_\_ on *(date)* \_\_\_\_\_; or

I returned the subpoena unexecuted because: \_\_\_\_\_

Unless the subpoena was issued on behalf of the United States, or one of its officers or agents, I have also  
tendered to the witness the fees for one day's attendance, and the mileage allowed by law, in the amount of  
\$ \_\_\_\_\_.

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ \_\_\_\_\_.

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

*Server's signature*

*Printed name and title*

*Server's address*

Additional information regarding attempted service, etc.:

**Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)****(c) Place of Compliance.**

(1) **For a Trial, Hearing, or Deposition.** A subpoena may command a person to attend a trial, hearing, or deposition only as follows:

- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
  - (i) is a party or a party's officer; or
  - (ii) is commanded to attend a trial and would not incur substantial expense.

**(2) For Other Discovery.** A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
- (B) inspection of premises at the premises to be inspected.

**(d) Protecting a Person Subject to a Subpoena; Enforcement.**

(1) **Avoiding Undue Burden or Expense; Sanctions.** A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

**(2) Command to Produce Materials or Permit Inspection.**

(A) **Appearance Not Required.** A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.

(B) **Objections.** A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:

(i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.

(ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

**(3) Quashing or Modifying a Subpoena.**

(A) **When Required.** On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:

- (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
- (iv) subjects a person to undue burden.

(B) **When Permitted.** To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:

- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

(ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.

(C) **Specifying Conditions as an Alternative.** In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:

- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
- (ii) ensures that the subpoenaed person will be reasonably compensated.

**(e) Duties in Responding to a Subpoena.**

(1) **Producing Documents or Electronically Stored Information.** These procedures apply to producing documents or electronically stored information:

(A) **Documents.** A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.

(B) **Form for Producing Electronically Stored Information Not Specified.** If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.

(C) **Electronically Stored Information Produced in Only One Form.** The person responding need not produce the same electronically stored information in more than one form.

(D) **Inaccessible Electronically Stored Information.** The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

**(2) Claiming Privilege or Protection.**

(A) **Information Withheld.** A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:

- (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.

(B) **Information Produced.** If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

**(g) Contempt.**

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

BERGER &amp; MONTAGUE, P.C.

107547

REF. #	INVOICE #	INV. DATE	INVOICE AMOUNT	CLIENT
133337	12138 10914	10/09/2014	\$55.46	NEXIUM

THIS CHECK HAS A COLORED BACKGROUND AND CONTAINS MULTIPLE SECURITY FEATURES. SEE BACK FOR DETAILS.

**BERGER & MONTAGUE, P.C.**  
 1622 LOCUST STREET  
 PHILADELPHIA, PA 19103

THE HUNTINGTON NATIONAL BANK  
 COLUMBUS, OHIO 43216  
[huntington.com](http://huntington.com)

107547  
 CHECK NO.  
 56-1503412

PAY

ELLY FIVE and 46/100 Dollars

DATE

AMOUNT

10/09/2014 \$55.46

TWO SIGNATURES REQUIRED FOR AMOUNTS OVER \$5000.

TO THE TRANBAXY, INC.  
 ORDER  
 OF



VALID AFTER 180 DAYS

107547 00440000246 01892603216

**Attachment A**

Plaintiffs seek testimony from the Keeper of Records regarding business records produced by your company to which you have objected on authenticity, hearsay or "double hearsay" grounds, as stated on the spreadsheet named "Defendants\_ Objections to Plaintiffs\_Revised Exhibit List 10.06.2013xlsx.xlsx" sent by your counsel in this action to plaintiffs on October 6, 2014, a print-out of which is attached as Attachment B.

Plaintiffs seek testimony from the Keeper of Records concerning the authenticity of the documents and whether the document is a business record pursuant to Federal Rule of Evidence 803(6).

Testimony at the location listed on the subpoena will be given via contemporaneous audio/video transmission to the courtroom in Boston, Massachusetts at which trial in this matter will be taking place. If, in lieu of testifying via audio/video transmission, the Keeper of Records will agree to appear voluntarily in the Federal District Court for the District of Massachusetts, where this action is pending, in Boston, Massachusetts to testify, counsel for the company and the Keeper of Records should contact:

Thomas M. Sobol  
Hagens Berman Sobol Shapiro LLP  
55 Cambridge Parkway, Suite 301 - Cambridge, MA 02142  
(617) 475-1950

**Attachment B**

Ref#	Description	Date	Relevant Doc#	Additional Bates	REvised Objection
0001	Settlement Agreement (Ranbaxy)	04/14/2008	AZ-NX-MDL-00000005	AZ-NX-MDL-00000031	
0002	Distribution Agreement (Ranbaxy - Plendil)	04/14/2008	AZ-NX-MDL-00000032	AZ-NX-MDL-00000032	
0003	Distribution Agreement (Ranbaxy - Prilosec)	04/14/2008	AZ-NX-MDL-00000093	AZ-NX-MDL-00000154	
0004	Baliment Agreement	04/14/2008	AZ-NX-MDL-00000155	AZ-NX-MDL-00000160	
0005	Supply Agreement	04/14/2008	AZ-NX-MDL-00000161	AZ-NX-MDL-00000204	
0006	Tolling Agreement	04/14/2008	AZ-NX-MDL-00000205	AZ-NX-MDL-00000248	
0007	Development and Technology Transfer Agreement	06/04/2008	NEX-RBX 3509695	NEX-RBX 3509745	
0008	Quality Assurance Agreement (Chm)	12/15/2008	RAN-ESM 0676926	RAN-ESM 0676972	
0009	AstraZeneca project scope document from E. Teneberg to M. Flatt. Project Scope for Esomeprazole 2nd source.	01/07/2013	RAN-ESM 0676976	RAN-ESM 0677033	
0020	AstraZeneca project scope document from E. Teneberg to M. Flatt. Project Scope for Esomeprazole 2nd source.	10/05/2004	NEX-RBX 3525093	NEX-RBX 3525094	
0027	Ranbaxy spreadsheet, ANDA Portfolio Summary.	12/31/2005	RAN-ESM0096779	RAN-ESM0096790	Hearsay Incomplete; Relevance; Hearsay
0028	AstraZeneca document. Minutes of 34th Supply Committee Meeting on 7 Feb 2006 at Alderley Park.	02/07/2006	NEX-RBX 3525080	NEX-RBX 3525084	Hearsay
0030	AstraZeneca Supply Committee Agenda Paper. Omniprazole and Esomeprazole sourcing review.	02/07/2006	NEX-RBX 3525109	NEX-RBX 3525112	Hearsay
0032	AstraZeneca Project Closure document from E. Teneberg to R. Alves and S. Fithwick. Project Closure for Esomeprazole API 2nd source.	03/09/2006	NEX-RBX 3525085	NEX-RBX 3525088	Hearsay
0033	E-mail from S. Lanik to K. Guenette with attached Plendil spreadsheets	12/13/2006	NEX-RBX 3485798	NEX-RBX 3485789	Hearsay Authenticity; Hearsay
0037	E-mail from J. Todisco to R. Johnson	05/22/2007	RAN-ESM0233747	RAN-ESM0233749	
0038	E-mail from J. Deshmukh to J. Pott	07/30/2007	NEX-RBX 0000001	NEX-RBX 0000001	
0039	E-mail from S. Pandit to J. Todisco with attached spreadsheet	08/08/2007	RAN-ESM0231243	RAN-ESM0231279	Relevance; Hearsay
0040	E-mail from S. Pandit to J. Todisco with attached spreadsheet	08/09/2007	RAN-ESM0232274	RAN-ESM0232440	Relevance; Hearsay
0041	E-mail from S. Pandit to J. Todisco with attached spreadsheet	08/16/2007	RAN-ESM0232441	RAN-ESM 0232607	Relevance; Hearsay
0042	E-mail from J. Deshmukh to J. Pott, M. Heifetz and W. Krovatin	08/23/2007	NEX-RBX 0000002	NEX-RBX 0000003	
0043	Greenstone Ltd. presentation by Bill Kennally. Authorized Generics (AGs) What's Changed? Presented at 8th Annual Generic Drug Summit, Institute for International Research.	09/01/2007	RAN-ESM0173010	RAN-ESM0173035	
0044	Email from G. Mehrotra to P. Nath and L. Ahluwalia with attached presentations	09/21/2007	RAN-ESM0172964	RAN-ESM0173035	Authenticity; Double Hearsay; Hearsay
0045	E-mail from D. Adams to P. Safir with attached letter from Ranbaxy to FDA	10/17/2007	NEX-RBX 0000004	NEX-RBX 0000013	
0046	E-mail from D. Adams to P. Safir with attached letter from Ranbaxy to FDA	10/31/2007	NEX-RBX 0000008	NEX-RBX 0000005	Hearsay; Relevance
0049	E-mail from J. Deshmukh to J. Pott	11/08/2007	NEX-RBX 3510039	NEX-RBX 3510039	Foundation; Hearsay
0051	E-mail from A. Aborlez to J. Pott	11/16/2007	NEX-RBX 3508565	NEX-RBX 3508567	Double Hearsay; Hearsay; Incomplete
0055	E-mail from T. Lester to L. Fales with attached draft Settlement Agreement	12/04/2007	NEX-RBX 0000014	NEX-RBX 0000036	

Ex#	Description	Date	Bet Doc#	End Doc#	Additional Bates#	Revised Objection
0056	E-mail from J. Pott to A. Abolezz	12/12/2007	NEX-RBX 3510044		NEX-RBX 3510045	Double Hearsay; Hearsay
0059	E-mail from J. Pott to A. Abolezz	12/14/2007	RAN-ESM 0248372	RAN-ESM 0248373	RAN-ESM 0248373	Relevance
0060	E-mail from L. Fales to T. Hester with attached draft settlement agreement	12/17/2007	NEX-RBX 0000039	NEX-RBX 0000068		
0062	AstraZeneca document, 2008 US Product Strategic Plan; NEKULM...	12/18/2007	AZ-NX-NDL-00873061	AZ-NX-NDL-00873088		
0064	E-mail from T. Hester to J. Adams with attached draft Settlement Agreement	01/05/2008	NEX-RBX 0000069	NEX-RBX 0000094		Hearsay
0067	E-mail from J. Deshmukh to A. Abolezz	01/08/2008	RAN-ESM 0248367	RAN-ESM 0248369	RAN-ESM 0248369	
0073	E-mail from A. Abolezz to T. Bowman, P. Larson and J. Deshmukh	01/17/2008	NEX-RBX 3510465	NEX-RBX 3510470	NEX-RBX 3510470	Hearsay; Relevance
0074	E-mail from B. Winter to Venkatachalam K. and J. Meehan	01/17/2008	RAN-ESM 0203334	RAN-ESM 0203335	RAN-ESM 0203335	Hearsay
0077	E-mail from P. Nath to Venkatachalam K. with attached forecast spreadsheets for Amlodipine + Atorvastatin, Donepezil, Esomeprazole, Memantine, Losartan and Pioglitazone	01/29/2008	RAN-ESM 0203360	RAN-ESM 0203401	RAN-ESM 0203401	
0078	E-mail from M. McCourt to M. Ladha with attachments	01/30/2008	NEX-RBX 3485910	NEX-RBX 3485913	NEX-RBX 3485913	Hearsay
0081	E-mail from J. Tolisco to Venkatachalam K.	02/05/2008	RAN-ESM 0203418	RAN-ESM 0203418	RAN-ESM 0203418	Hearsay
0084	E-mail from A. Kalra to multiple recipients	03/07/2008	RAN-ESM 0222944	RAN-ESM 0222945	RAN-ESM 0222945	Authenticity; Hearsay
0085	E-mail from A. Kalra to O. Sethi and P. Gupta with attached Key Country Growth Drivers CAGR 2008-2012 spreadsheet, Value Drivers MNs Feb 2008 presentation, FTF Questions Part II document, FTF Questions document and GCSF Financial Analysis spreadsheet	03/10/2008	RAN-ESM 0222974	RAN-ESM 0222976	RAN-ESM 0222980 - RAN-ESM 0222990; RAN-ESM 0223029 - RAN-ESM 0223032; RAN-ESM 0223037 - RAN-ESM 0223041	Authenticity; Double Hearsay; Hearsay
0086	Memo from K. Monday to M. McCourt; Esomeprazole Magnesium 20mg and 40mg Capsules.	03/26/2008	NEX-RBX 3514304	NEX-RBX 3514305	NEX-RBX 3514305	Incomplete; Relevance; Hearsay
0089	E-mail from B. Zimmerman to T. Hester, J. Deshmukh, A. Abolezz and D. Adams	04/08/2008	NEX-RBX 0000226	NEX-RBX 0000227	NEX-RBX 0000227	Hearsay
0090	E-mail from J. Deshmukh to T. Hester, A. Abolezz, B. Zimmerman and D. Adams	04/08/2008	NEX-RBX 0000228	NEX-RBX 0000228	NEX-RBX 0000228	Hearsay
0093	E-mail from J. Deshmukh to J. Pott	04/09/2008	NEX-RBX 3508998	NEX-RBX 3508999	NEX-RBX 3508999	Hearsay
0107	E-mail from J. Deshmukh to T. Hester, J. Pott, A. Abolezz, D. Adams and B. Zimmerman	04/14/2008	NEX-RBX 0000362	NEX-RBX 0000362	NEX-RBX 0000362	Hearsay
0115	Collection of press releases and press reports regarding the AstraZeneca Ranbaxy Naxium settlement and manufacturing/distribution agreements	04/15/2008	NEX-RBX 3429510	NEX-RBX 3429522	NEX-RBX 3429522	J&B Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial!

Reference	Description	Date	BerDoc	EndDoc	Additional Bates	REvised Objection
0117	E-mail from S. Safaya to undisclosed recipients	04/16/2008	RAN-ESM091944	RAN-ESM0091944		Authenticity; Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial
0118	E-mail from A. Kaira to multiple recipients	04/16/2008	RAN-ESM0202889	RAN-ESM0202990		Foundation; Hearsay; Incomplete
0120	AstraZeneca minutes. Esomeprazole: Initial meeting on activities relating to Outsourcing of esomeprazole (API), 23 April 2008.	04/23/2008	NEX-RBX 3525374	NEX-RBX 3525376		Hearsay
0124	Letter from AstraZeneca counsel to the FTC	05/02/2008	AZ-NX-MDL-00968287	AZ-NX-MDL-00968288		Hearsay; Prejudice
0127	E-mail from Tl Easwar to V. Madan with attached Agenda	05/06/2008	RAN-ESM0229361	RAN-ESM0229363		
0139	AstraZeneca memo. Minutes and Action Items from AZ/Ohm Meeting, May 6, 2008.	05/12/2008	NEX-RBX 3513636	NEX-RBX 3513638		
0159	E-mail from P. Rajan to S. Pandit with attached Esomeprazole Forecast spreadsheet	07/03/2008	RAN-ESM0188701	RAN-ESM0188725		Double Hearsay; Hearsay
0161	E-mail from S. Rajan to S. Pandit with attached Esomeprazole Capsules DR Executive Summary	07/03/2008	RAN-ESM0188737	RAN-ESM0188762		Relevance; Hearsay
0162	Civil Investigative Demand to Ranbaxy, FTC File No. 0810171	07/03/2008	RAN-ESM0248120	RAN-ESM0248138		Authenticity; Hearsay; Relevance
0165	Transcript of investigational hearing, Jeffrey A. Pett, FTC File No. 0810171	07/23/2008	AZ-NX-MDL-00968317	AZ-NX-MDL-00968411		Authenticity; Hearsay; Unfairly Prejudicial
0167	Transcript of investigational hearing, Jay Deshmukh, FTC File No. 0810171	08/28/2008	RAN-ESM 0248233	RAN-ESM 0248286		Double Hearsay; Hearsay; Improper Exhibit (deposition transcript); Unfairly Prejudicial
0168	E-mail from J. Todisco to G. Mehrotra, L. Ahluwalia and Venkatachalam K. with attached spreadsheets	01/08/2009	RAN-ESM 0488181	RAN-ESM 0488222		Hearsay; Improper Exhibit (deposition transcript)
0169	E-mail from A. Jain to J. Todisco with attached New Products 2009-2011 spreadsheet	01/10/2009	RAN-ESM 0468752	RAN-ESM 0468758	RAN-ESM 0468764 - RAN-ESM 0468771	Hearsay; Relevance
0170	E-mail from L. Ahluwalia to A. Jain and J. Todisco	01/11/2009	RAN-ESM 0438757	RAN-ESM 0438769	RAN-ESM 0438769	Hearsay; Incomplete; Relevance
0175	Response to Civil Investigative Demand Issued by the Federal Trade Commission to Ranbaxy on July 3, 2008 in File No. 0810171	04/15/2009	RAN-ESM0248153	RAN-ESM0248191	RAN-ESM0248191	Hearsay; Relevance
0176	Email from Ranbaxy counsel to FTC with attached letter, Supplemental Responses to interrogatories, and Attachment C	05/04/2009	RAN-ESM0248192	RAN-ESM0248199	RAN-ESM0248199	Unfairly Prejudicial; Hearsay
0177	AstraZeneca's Responses to Civil Investigative Demand Interrogatory Specifications, FTC File No. 0810171	05/29/2009	AZ-NX-MDL-00968222	AZ-NX-MDL-0096837	AZ-NX-MDL-0096837	Unfairly Prejudicial; Hearsay
0181	AstraZeneca's Supplemental Response to Civil Investigative Demand Interrogatory Specification Number 13, FTC File No. 0810171	09/03/2009	AZ-NX-MDL-00903638	AZ-NX-MDL-00903639	AZ-NX-MDL-00903639	Hearsay; Unfairly Prejudicial
0182	E-mail from J. Todisco to C. Caprafield with attached Ranbaxy US Business Overview presentation	09/15/2009	RAN-ESM 0469012	RAN-ESM 0469083	RAN-ESM 0469083	Double Hearsay; Hearsay; Unfairly Prejudicial
0192	Minutes from AZ Steering Committee Meeting on February 10, 2010	03/15/2010	RAN-ESM 0297861	RAN-ESM 0297864	RAN-ESM 0297864	Misleading; Relevance; Hearsay
						Incomplete; Relevance; Hearsay

P.R.E.	Description	Date	RebDoc	EndDoc	Additional Notes	REVISION/CORRECTION
0195	Email - Ranbaxy Email string re: AZ/Ranbaxy and Ohm accounts	05/21/2010	RAN-ESM 0205319	RAN-ESM 0295325		Authenticity; Hearsay; Relevance
0215	E-mail from R. Riccobon to S. Sanade	07/11/2011	RAN-ESM 0308401	RAN-ESM 0308402		Authenticity; Hearsay; Relevance
0216	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	08/16/2011	RAN-ESM 0313413	RAN-ESM 0313428		Authenticity; Hearsay; Relevance
0217	E-mail from FTC to Ranbaxy counsel with attached Second Civil Investigative Demand to Ranbaxy, FTC File No. 0810171	08/23/2011	RAN-ESM0248200	RAN-ESM0248212		Authenticity; Hearsay; Relevance
0218	Transcript of Investigational hearing, Richard Barker, FTC File No. 0810171	09/01/2011	AZ-NX-MDL-00968186	AZ-NX-MDL-00968235		Authenticity; Hearsay; Unfairly Prejudicial
0219	E-mail from Pandi to Blank RE: Esomeprazole [9.6.11]	09/12/2011	RAN-ESM 0457647	RAN-ESM 0457647		Double Hearsay; Hearsay; Unfairly Prejudicial
0220	Transcript of Investigational hearing, David Pitman Snow, FTC File No. 081071	09/21/2011	AZ-NX-MDL-00968236	AZ-NX-MDL-00968285		Authenticity; Hearsay; Relevance
0222	Letter from AstraZeneca counsel to FTC with attached AstraZeneca's Responses to Second Civil Investigative Demand Interrogatory Specification, FTC File No. 0810171	09/30/2011	AZ-NX-MDL-00903645	AZ-NX-MDL-00003659		Double Hearsay; Hearsay; Unfairly Prejudicial
0224	Response to Second Civil Investigative Demand Issued by the Federal Trade Commission to Ranbaxy on August 19, 2011, FTC File No. 0810171	09/30/2011	RAN-ESM0248218	RAN-ESM0248226		Hearsay; Incomplete; Unfairly Prejudicial
0229	Agenda for AZ Ohm Laboratories Sales & Operations Planning Meeting, 2012 January Forecast for Capsules from Ohm to Astra USA; 2011 December API Forecast from Ohm to Astra USA; Capsule and API Purchase Order lists; API Shipment Delivery Updates	01/17/2012	RAN-ESM 0305682	RAN-ESM 0305689		Unfairly Prejudicial; Hearsay
0230	Agenda for AZ Ohm Laboratories Sales & Operations Planning Meeting, 2012 February Forecasts for Capsules from Ohm to Astra USA; 2012 January API Forecast from Ohm to Astra USA; Capsule and API Purchase Order lists; Shipment Delivery Updates; E-mail from J. McCabe to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	02/14/2012	RAN-ESM 0318200	RAN-ESM 0318223		Incomplete; Hearsay; Relevance
0232	Ranbaxy spreadsheet, Econoprazole Forecast - Iva Loss.	03/01/2012	RAN-ESM0234301	RAN-ESM0234449		Hearsay; Relevance
0234	E-mail from J. McCabe to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	03/09/2012	RAN-ESM 0318151	RAN-ESM 0318174		Incomplete; Hearsay; Relevance
0236	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	04/16/2012	RAN-ESM 0257934	RAN-ESM 0257936		Hearsay; Relevance
						Hearsay; Relevance

Ref.	Description	Date	Brd Doc	End Date	Additional Bates	REVISED OBJECTION
0237	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	05/14/2012	RAN-ESM 0256975	RAN-ESM 0256998		Hearsay, Relevance
0238	E-mail from J. McAfee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	05/12/2012	RAN-ESM 0301034	RAN-ESM 0301056		Hearsay, Relevance
0240	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	07/17/2012	RAN-ESM 0255913	RAN-ESM 0255935		Hearsay, Relevance
0244	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	08/15/2012	RAN-ESM 0255225	RAN-ESM 0255248		Hearsay, Relevance
0245	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	09/19/2012	RAN-ESM 0254369	RAN-ESM 0254391		Incomplete; Hearsay, Relevance
0246	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	10/16/2012	RAN-ESM 0253962	RAN-ESM 0253985		Incomplete; Hearsay, Relevance
0247	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	11/14/2012	RAN-ESM 0253588	RAN-ESM 0253611		Hearsay, Relevance
0248	AstraZeneca/Ohm Laboratories - Sales & Operations Planning Meeting Agenda	12/12/2012	RAN-ESM 0253488	RAN-ESM 0253510		Incomplete; Hearsay, Relevance
0249	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	01/16/2013	RAN-ESM 0263997	RAN-ESM 0263919		Incomplete; Hearsay, Relevance
0252	AstraZeneca/Ohm Laboratories - Sales & Operations Planning Meeting Agenda	03/20/2013	RAN-ESM 0286596	RAN-ESM 0286616		Incomplete; Hearsay, Relevance
0253	E-mail from J. McAfee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	04/15/2013	RAN-ESM 0286508	RAN-ESM 0286529		Incomplete; Hearsay, Relevance
0254	Settlement Agreement [Teva - Phillips]	01/06/2010	AZ-NX-MDL-00000254	AZ-NX-MDL-00000295		Hearsay, Relevance
0255	Strategic Alliance Agreement Between Impax Laboratories, Inc. and Teva Pharmaceuticals Curacao N.V.	01/08/2003	Teva-ESO-098043	Teva-ESO-098047		Relevance
0261	E-mail from S. Julie to M. Heifetz with attached financial information	04/18/2006	Teva-ESO-023577	Teva-ESO-023578		Hearsay, Incomplete; Relevance
0271	Transcript of proceedings, No. 08-cv-08094 and No. MA-21-81 (S.D.N.Y.)	10/30/2008	AZ-NX-MDL-01015835	AZ-NX-MDL-01015844		Hearsay
0273	Letter from AstraZeneca counsel to Teva counsel with attached Astra's Responses to Defendant Teva's First Set of Interrogatories (Nos. 1-2) to Plaintiffs, No. 08-cv-00621 and No. M-21-81 (S.D.N.Y.)	12/02/2008	AZ-NX-MDL-01016193	AZ-NX-MDL-01016251		Hearsay
0274	E-mail from O. Vairi to S. Julie	12/04/2008	Teva-ESO-026869	Teva-ESO-026869		Hearsay
0275	Transcript of proceedings, No. 08-cv-02155 and No. 08-cv-02496 (D.N.J.)	12/17/2008	Teva-ESO-107633	Teva-ESO-107703		Foundation; Relevance

Index	Description	Date	Entered Doc	Additional Bates	REvised Objections
0278	Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-13); Related to Damages, Willful Infringement and Exceptional Case Determinations, No. 05-cv-00621 (S.D.N.Y.)	01/21/2009	AZ-NX-MDL-01016883	AZ-NX-MDL-01016944	
0279	Letter from AstraZeneca counsel to Teva counsel with attached Astral's Response to Defendant Teva's Second Set of Interrogatories (Nos. 3-17) to Plaintiff, No. 05-cv-00621 and No. M-21-81 (S.D.N.Y.)	01/23/2009	AZ-NX-MDL-01016958	AZ-NX-MDL-01016975	Hearsay
0280	Letter from John M. Grism, Jr., to Special Master Gail R. Peterson re: In re Omeprazole Patent Litigation, M-21-81 - AstraZeneca's Opposition to Teva's Motion to Compel Plaintiffs to Provide Documents and Information Relating to Damages. Attached Exhibit A is a letter from Mr. Grism to Ashley Gray dated 04/01/2009.	04/15/2009	Teva-ESO-112721	Teva-ESO-112742	Hearsay
0282	Transcript of conference call hearing, No. M-21-81 (S.D.N.Y.)	05/27/2009	AZ-NX-MDL-01017668	AZ-NX-MDL-01017821	Relevance; Unfairly Prejudicial
0283	AstraZeneca's Responses to Defendant Teva's Third Set of Interrogatories (Nos. 18-20) to Plaintiffs, No. 05-cv-00621 (S.D.N.Y.)	05/28/2009	AZ-NX-MDL-01017822	AZ-NX-MDL-01017853	Hearsay; Relevance; Unfairly Prejudicial
0284	Transcript of conference call hearing, No. 05-cv-00621 and No. M-21-81 (S.D.N.Y.)	06/19/2009	AZ-NX-MDL-01017951	AZ-NX-MDL-01018078	Hearsay; Relevance; Unfairly Prejudicial
0285	E-mail from T. Hester to D. Stark with attached draft Settlement Agreements	08/26/2009	AZ-NX-MDL-00002508	AZ-NX-MDL-00002556	Double Hearsay; Hearsay; Unfairly Prejudicial
0286	E-mail from K. Keen to M. Heifetz with attached draft Settlement Agreements	09/09/2009	AZ-NX-MDL-00001753	AZ-NX-MDL-00001753	
0287	E-mail from T. Hester, Timothy to multiple recipients with attached revised draft settlement agreements	10/07/2009	AZ-NX-MDL-00002106	AZ-NX-MDL-00002106	
0289	E-mail from K. Keen to T. Hester	11/13/2009	AZ-NX-MDL-00001859	AZ-NX-MDL-00001859	Hearsay; incomplete
0290	E-mail from T. Hester to K. Kean	12/02/2009	AZ-NX-MDL-00001984	AZ-NX-MDL-00001984	Hearsay; incomplete
0292	E-mail from T. Hester to K. Kean and S. Julie	12/08/2009	AZ-NX-MDL-00002216	AZ-NX-MDL-00002216	Hearsay; incomplete
0293	E-mail from K. Keen to T. Hester	12/15/2009	AZ-NX-MDL-00002341	AZ-NX-MDL-00002342	Hearsay; incomplete
0294	E-mail from T. Hester to K. Kean	12/17/2009	AZ-NX-MDL-00002557	AZ-NX-MDL-00002557	Hearsay; incomplete
0295	E-mail from Taft, Kingley to Hester, Timothy RE: Omeprazole and Esomeprazole Settlement Agreements; Subject to Federal Rule of Evidence 408; attaching Settlement Agreement (esomeprazole).DOC	12/19/2009	AZ-NX-MDL-00002469	AZ-NX-MDL-00002470	Hearsay; incomplete

PIR#	Description	Date	End Date	Additional Date	REvised objection
0297	E-mail from Test, Kingsley to Hester, Timothy regarding Omeprazole and Esomeprazole Settlement Agreements and PR attaching PR Redline.doc; TEVA AZ PR draft 04012010.doc; Execution Version Omeprazole Prilosec Agreement.DOC; Execution Version Esomeprazole_Nexium Agreement.DOC; Redline - omeprazole.doc; Redline - esomeprazole.doc	01/05/2010	AZ-NX-MDL-00002682	AZ-NX-MDL-00002662	
0299	Nexium (esomeprazole) Product Brief 01/01/2011	AZ-NX-MDL-00054551	AZ-NX-MDL-00854551	Hearsay; incomplete	
0300	Settlement Agreement (DRL)	01/18/2011	AZ-NX-MDL-00000331	AZ-NX-MDL-00000366	Hearsay
0302	E-mail from A. Miller to J. Rhillinger with attachments	12/23/2008	DRIMDL 180154	DRIMDL 180165	
0312	E-mail from Ajay Singh to Lee Banks and Anjum Swaroop re: Fw: Meeting and thank you	07/22/2010	DRIMDL 173252	DRIMDL 173254	
0324	E-mail from A. Singh to M. Heifetz with attached Brain-storming sheet	09/20/2010	AZ-NX-MDL-00003394	AZ-NX-MDL-00003395	Relevance; Unfairly Prejudicial; Relevance; [Accolate]
0325	E-mail from M. Heifetz to A. Singh	09/21/2010	AZ-NX-MDL-00003396	AZ-NX-MDL-00003398	Hearsay; Relevance; Unfairly Prejudicial; [Accolate]
0327	E-mail from A. Singh to A. Miller, A. Patel and L. Banks	10/13/2010	DRIMDL 233091	DRIMDL 263052	Hearsay; Relevance; Unfairly Prejudicial; [Accolate]
0346	E-mail from A. Singh to A. Mukherjee	12/30/2010	DRIMDL 172348	DRIMDL 172348	Authenticity; Hearsay
0347	E-Mail from Heifetz, Marcus to Ajay Singh Regarding Basic overview of proposal to settle litigations	12/31/2010	AZ-NX-MDL-00001572	AZ-NX-MDL-00001572	Unfairly Prejudicial; Relevance; [Accolate]
0348	E-mail from A. Singh to M. Heifetz	01/01/2011	AZ-NX-MDL-00002809	AZ-NX-MDL-00002810	Hearsay; Unfairly Prejudicial; Relevance; [Accolate]
0349	E-mail from T. Hester to A. Singh and L. Banks	01/03/2011	AZ-NX-MDL-00001430	AZ-NX-MDL-00001430	Unfairly Prejudicial; Relevance; [Accolate]
0350	E-mail from Hester, Timothy to Andrew Miller regarding Nexium/Accolate attaching AZ.DRL.Nexium agreement.DOC; CV_Cmparison #3846193v3_DC_- AZ.DRL.Nexium_agreement.January 3-#3846193v4_DC_- AZ.DRL.Nexium agreement.doc	01/05/2011	AZ-NX-MDL-00001361	AZ-NX-MDL-00001361	Hearsay; Unfairly Prejudicial; Relevance; [Accolate]
0354	E-mail from Hester, Timothy to Andrew Miller regarding regarding Nexium/Accolate with copy Draft Settlement Agreement.DOC; Settlement Agreement - Draft - between AZ, KBL, Merck and DRIM	01/05/2011	DRIMDL 171402	DRIMDL 171437	Hearsay; Unfairly Prejudicial; Relevance; [Accolate]
0357	E-mail from Ajay Singh to multiple recipients re Esomeprazole Settlement Update	01/06/2011	DRIMDL 172884	DRIMDL 172884	Authenticity; Hearsay; Unfairly Prejudicial; Relevance; [Accolate]
0364	E-mail from Hester, Timothy to Andrew Miller regarding Execution Versions of Settlement Agreements attaching AZ.DRL.Accolite Agreement.DOC; AZ.DRL.Nexium Agreement.DOC; AZ.DRL press release.DOC	01/17/2011	AZ-NX-MDL-00001486	AZ-NX-MDL-00001486	Unfairly Prejudicial; Relevance; [Accolate]
					Hearsay; incomplete; Unfairly Prejudicial; Relevance; [Accolate]

Exhibit	Description	Date	BeiDot	EndDot	Additional Bates	REVISED OBJECTION
0366	E-mail from Hester, Timothy to Andrew Miller regarding Execution Versions of Settlement Agreements with copies of Settlement Agreement between AZ, KBI, Merck and DRL	01/17/2011	DRLMDL 171349	DRIMDL 171597		Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0367	Email from A. Singh to A. Mukherjee	01/17/2011	DRIMDL 234405	DRIMDL 234407		Authenticity; Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0372	E-mail from A. Miller to P. Schaefer with attached Settlement Agreements	01/25/2011	DRIMDL 171640	DRIMDL 171692		Authenticity; Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0376	Settlement Agreement [Sandos]	05/11/2011	AZ-NX-MDL-00000383	AZ-NX-MDL-00000416		
0377	Settlement Agreement [Lupin]	01/10/2012	AZ-NX-MDL-00000417	AZ-NX-MDL-00000455		
0378	Settlement Agreement [Hetero]	04/10/2012	AZ-NX-MDL-00000456	AZ-NX-MDL-00000485		
0379	Settlement Agreement [Tarrant]	05/01/2012	AZ-NX-MDL-00000524	AZ-NX-MDL-00000524		
0380	AstraZeneca document. Product: Esomeprazole, Request for Proposal to Suppliers.	05/16/2005	AZ-NX-MDL-00773363	AZ-NX-MDL-00773363		Hearsay
0382	E-mail from C. Tissun to R. Barker and G. Backlund	08/16/2007	NEX-RBX 3514361	NEX-RBX 3514365		Double Hearsay; Hearsay
0384	Presentation from AZ entitled "Genesis" with information re: Formulation/Packaging Strategy and High Level Timeline (redactions)	08/17/2007	NEX-RBX 3505851	NEX-RBX 3505857		
0385	AstraZeneca document. Genesis—Generic Landscape Talking Points..	08/21/2007	NEX-RBX 3514334	NEX-RBX 3514334		Hearsay
0386	E-mail from Myers, Mary Ellen to Barker, Richard S.; McCarthy, John A. (CBL) regarding Genesis Template attaching Genesis TalkingPoints.doc	08/22/2007	NEX-RBX 3514332	NEX-RBX 3514333		Authenticity; Hearsay
0387	E-mail from S. Rothwein to R. Barker	08/25/2007	NEX-RBX 3514365	NEX-RBX 3514366		Hearsay; Incomplete
0388	E-mail from Barker, Richard S. to McCarthy, John A (CBL) regarding Genesis	09/10/2007	NEX-RBX 3503198	NEX-RBX 3503198		Hearsay
0389	E-mail from Richard S. Barker to John A. McCarthy, Marion McCourt re: Genesis info	09/17/2007	NEX-RBX 3525168	NEX-RBX 3525168		Double Hearsay; Hearsay
0392	E-mail from Barker, Richard S. to multiple recipients regarding Genesis Volumes	10/24/2007	NEX-RBX 3514367	NEX-RBX 3514367		Hearsay
0395	E-mail from Richard S. Barker to Kathy Monday, Stephen Macrides with CC to Eleanor Lorenz RE: Nexium AG Consent (redactions)	10/29/2007	NEX-RBX 3514399	NEX-RBX 3514400		Hearsay
0396	E-mail from R. Baker to K. Monday and S. Macrides	10/29/2007	NEX-RBX 3514401	NEX-RBX 3514403		Double Hearsay; Hearsay
0397	AstraZeneca presentation. Potential NEXIUM AG	11/07/2007	AZ-NX-MDL-01243697	AZ-NX-MDL-01243706		Double Hearsay; Hearsay
0398	E-mail from Brazzo, John P. to McCourt, Marion, McCarthy, John A (CBL) regarding Privileged and Confidential - Attorney Work Product - Final Genesis Slides Deck for Merck Discussion attaching Genesis - MarchFinal.ppt	11/07/2007	NEX-RBX 3505858	NEX-RBX 3505859		Hearsay
0399	E-mail from J. McCarthy, R. Barker, J. Brazzo and M. McCourt	11/08/2007	NEX-RBX 3505870	NEX-RBX 3505873		Hearsay; Incomplete

Exhibit	Description	Date	Exhibit#	Exhibit#	Additional Dates	REvised Document
0400	AstraZeneca presentation: Potential NEXIUM AG Overview, November 12, 2007	11/12/2007	NEX-RBX 3456119		NEX-RBX 3456128	
0401	Memo from Tim Lawes to Jerker Sandburg and Rick Barker regarding Establish Generic Esomeprazole Mg with attached Capsugel Color Code - 05.377; Capsugel Ink Code - 1014; Print	11/13/2007	NEX-RBX 3515016		NEX-RBX 3515025	
0402	E-mail from J. Brazzo to multiple recipients with attached Project Genesis Slide - Financials/Forecast - Page 7 of Slide Deck	11/16/2007	AZ-NX-MDL-01243691		AZ-NX-MDL-01243692	
0403	Letter from AstraZeneca to KBL-E, Inc. c/o Merck & Co., Inc. providing information regarding discussions of initializing with third parties with respect to distributing an authorized generic version of pantoprazole (esomeprazole magnesium).	11/16/2007	NEX-RBX 3505876		NEX-RBX 3505878	
0404	AstraZeneca presentation: Genesis Forecast.	11/20/2007	AZ-NX-MDL-01015763		AZ-NX-MDL-01015766	
0405	AstraZeneca presentation: Genesis Forecast.	11/20/2007	AZ-NX-MDL-01243693		AZ-NX-MDL-01243696	
0407	E-mail from R. Barker to K. Lundgren-Hartikainen, C. Trulsson and P. Pican with attached Potential Nexium® AG Overview	11/27/2007	NEX-RBX 3514442		NEX-RBX 3514453	
0408	E-mail from R. Barker to K. Monday	12/04/2007	NEX-RBX 3514456		NEX-RBX 3514456	
0409	E-mail from Barker, Richard S. to Monday, Kathy regarding Genesis	12/05/2007	NEX-RBX 3514336		NEX-RBX 3514337	
0410	E-mail from K. Monday to R. Barker	12/19/2007	NEX-RBX 3514460		NEX-RBX 3514464	
0413	AstraZeneca presentation: Nexium Plan B - Working Session, Scenario Review and Discussion.	04/07/2008	NEX-RBX 3505840		NEX-RBX 3505850	
0414	E-mail from R. Barker to M. McCourt and J. McCarthy	04/14/2008	NEX-RBX 3505881		NEX-RBX 3505881	
0415	E-mail from R. Barker to M. McCourt and J. McCarthy	05/12/2008	NEX-RBX 3514306		NEX-RBX 3514306	
0416	E-mail from R. Barker to L. Urban	05/16/2008	NEX-RBX 3514307		NEX-RBX 3514307	
0417	E-mail from M. McCourt to R. Farite	07/29/2008	AZ-NX-MDL-00864316		AZ-NX-MDL-00864317	
0418	E-mail from N. Lewis to R. Barker	09/05/2008	AZ-NX-MDL-01020593		AZ-NX-MDL-01020593	
0421	E-mail from K. Singh to J. Tremayne	12/17/2008	AZ-NX-MDL-00911971		AZ-NX-MDL-00911971	
0423	E-mail from B. Swerves to J. Brazzo	01/21/2009	AZ-NX-MDL-00913116		AZ-NX-MDL-00913119	
0424	E-mail from F. Racagniere to R. Barker and M. Olson with attached Nexium Scenario Volume Summaries spreadsheet.	03/19/2009	AZ-NX-MDL-00911218		AZ-NX-MDL-00911219	
0425	E-mail from R. Barker to A. Grilgaard	03/03/2010	AZ-NX-MDL-00930861		AZ-NX-MDL-00930862	
0428	E-mail from R. Barker to S. Macrides	05/04/2010	AZ-NX-MDL-00966153		AZ-NX-MDL-00966155	
0429	E-mail from S. Macrides to R. Barker	05/10/2010	AZ-NX-MDL-00943390		AZ-NX-MDL-00943393	
0430	Presentation: Branded and Generic Threats to Nexum, March 31, 2011	03/31/2011	AZ-NX-MDL-00830356		AZ-NX-MDL-00830356	
0431	E-mail from S. Macrides to M. Crawford, K. Monday and R. Stellion	09/09/2011	AZ-NX-MDL-00949435		AZ-NX-MDL-00949436	

Case No.	Description	Date	Brief Doc#	End Doc#	Additional Brief#	REVISED OBJECTION
0451	Strategic Alliance Agreement between Teva Pharmaceuticals Curacao N.V. and Impax Laboratories, Inc.	06/26/2001	Teva-ESO-098048	Teva-ESO-098048		Authenticity; Incomplete
0452	IMPAX press release. IMPAX receives FDA approval for omeprazole, a generic version of Prilosec.	11/11/2002	[no bates]			
0453	IMPAX press release. IMPAX and Teva launch omeprazole delayed release capsules 20mg.	09/08/2004	[no bates]			
0454	Complaint and Summons, Dkt. 1, No. 03-cv-00621 (S.D.N.Y.)	01/14/2005	Teva-ESO-025051	Teva-ESO-025051		Hearsay
0455	Teva Press release. Teva completes acquisition of MAXX.	01/26/2006	[no bates]			Hearsay; Incomplete
0456	Letter from Teva counsel to PriceWaterhouse Coopers. Redlined.	03/08/2006	Teva-ESO-090325	Teva-ESO-090331		Authenticity; Incomplete
0457	IMPAX press release. IMPAX announces decision on generic Prilosec® litigation.	06/01/2007	[no bates]			
0458	Wall Street Journal article. AstraZeneca settles Ranbaxy patent suit.	04/16/2008	[no bates]			Authenticity; Double Hearsay; Hearsay
0459	Special Master's Interim Order on Proposed Protective Order, No. 05-cv-00621 (S.D.N.Y.)	03/16/2009	AZ-NX-MDL-01017448	AZ-NX-MDL-01017486		Hearsay; Relevance
0460	Settlement Agreement [Teva - Prilosec], Executed by Teva/Impax only.	01/06/2010	AZ-NX-MDL-00001072	AZ-NX-MDL-00001098		
0461	Settlement Agreement (DRL) Draft.	01/15/2011	AZ-NX-MDL-00001596	AZ-NX-MDL-00001662		Hearsay; Incomplete
0463	Ranbaxy press release. Ranbaxy and AstraZeneca reach agreement in esomeprazole patent litigation.	undated	[no bates]			Authenticity; Double Hearsay; Hearsay
0465	Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-6) Related to Teva's Relationship with Impax, No. 05-cv-00621 (S.D.N.Y.)	12/24/2008	AZ-NX-MDL-01016544	AZ-NX-MDL-01016574		
0467	UBS Investment Research Report.	04/15/2008	RAN-EMD0202999	RAN-EMD0202998		Hearsay
0468	E-mail from A. Paulina to J. Berlanska Ranbaxy.	01/20/2010	Teva-ESO-039266	Teva-ESO-039266		Hearsay; Relevance
0469	Teva Pharmaceutical Industries Limited, Form 6-K	11/07/2008	[no bates]			Relevance
0470	Letter from AstraZeneca counsel to FTC	09/03/2009	AZ-NX-MDL-00003640	AZ-NX-MDL-00003642		Hearsay; Unfairly Prejudicial
0471	Letter from AstraZeneca counsel to FTC with attached Appendix	10/11/2013	AZ-NX-MDL-01270564	AZ-NX-MDL-01270568		Hearsay; Unfairly Prejudicial
0472	Defendant's Teva Pharmaceuticals' Brief in Support of Their Motion to Lift Stay of Proceedings, Dkt. 29, No. 05-cv-00621 (S.D.N.Y.)	02/21/2006	[no bates]			
0473	Brain-storming Sheet and e-mail from M. Heifetz to A. Singh	09/22/2010	AZ-NX-MDL-00003395	AZ-NX-MDL-00003398		Hearsay; Relevance; Cumulative; Double Hearsay; Hearsay; Incomplete; Misleading; Not a proper summary under Rule 1006; Unfairly Prejudicial
0474	Rule 1006 Summary of Ranbaxy Agreement-Related Exhibits	undated	[no bates]			

Reference	Description	Date	Be Doc#	End Date	Additional Notes	REVISED OBJECTION
0475	Rule 2006 Summary of Teva Agreement-Related Exhibits	undated	[no Bates]			Authenticity; Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006; Unfairly Prejudicial
0476	Rule 2006 Summary of DRL Agreement-Related Exhibits	undated	[no Bates]			Authenticity; Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006; Unfairly Prejudicial
0478	Invoices to AstraZeneca for Ranbaxy Nexium capsules supply	undated	AZ-NX-MDL-01243590	AZ-NX-MDL-01243685		Hearsay
0479	AstraZeneca presentation, Potential NEXUMA® AG Overview.	11/07/2008	NEX-RBX 3505860	NEX-RBX 3505869		Hearsay
0480	E-mail from G. Backlund to R. Barker	08/15/2007	NEX-RBX 3514354	NEX-RBX 3514356		Hearsay
0481	E-mail from B. Viscusi to R. Barker with attached presentation	02/25/2008	NEX-RBX 3514368	NEX-RBX 3514375		Hearsay
0482	Dr. Reddy's Q2 FY11 Financial Result Release	01/25/2011	AZ-NX-MDL-00003399	AZ-NX-MDL-00003402		Authenticity; Double Hearsay; Hearsay; Relevance; Unfairly Prejudicial (Accordia)
0483	Attachment to e-mail from T. Lester to A. Singh and L. Banks (draft Nexium settlement agreement)	01/03/2011	AZ-NX-MDL-00001431	AZ-NX-MDL-00001463		
0485	E-mail from D. Stark to S. Julie	08/04/2009	Teva-ESO-023584	Teva-ESO-023587		Authenticity; Hearsay
0486	E-mail from S. Julie to P. Jeffrey	01/02/2010	Teva-ESO-023674	Teva-ESO-023676		Authenticity; Hearsay; Incomplete
0501	File wrapper for United States Patent Application Serial No. 06/254,739 ('974 patent)	04/21/1986	DPCP-Patent-00000001	DPCP-Patent-00000506		
0502	File wrapper for United States Patent Application Serial No. 07/040,490 ('230 patent)	04/20/1987	DPCP-Patent-0000619	DPCP-Patent-0000759		
0503	File wrapper for United States Patent Application Serial No. 07/040,491 ('505 patent)	04/20/1987	DPCP-Patent-0000507	DPCP-Patent-0000618		
0504	File wrapper for United States Patent Application Serial No. 08/213,036 ('960 patent)	09/27/1994	DPCP-Patent-0000760	DPCP-Patent-0000957		
0505	File wrapper for United States Patent Application Serial No. 08/213,342 ('124 patent)	09/27/1994	DPCP-Patent-0000958	DPCP-Patent-0001218		
0506	File wrapper for United States Patent Application Serial No. 08/376,512 ('504 patent)	01/23/1995	DPCP-Patent-0001219	DPCP-Patent-0001675		
0507	Amendment and Response from file wrapper for United States Patent Application Serial No. 08/376,512	02/12/1997	DPCP-Patent-0001399	DPCP-Patent-0001412		Incomplete
0508	Declaration of Andersson from file wrapper for United States Patent Application Serial No. 08/376,512	02/12/1997	DPCP-Patent-0001416	DPCP-Patent-0001438		
0509	File wrapper for United States Patent Application Serial No. 08/492,087 ('788 patent)	07/03/1995	DPCP-Patent-0004245	DPCP-Patent-0004547		
0510	File wrapper for United States Patent Application Serial No. 08/833,962 ('192 patent)	04/11/1997	DPCP-Patent-0001676	DPCP-Patent-0002017		
0511	File wrapper for United States Patent Application Serial No. 09/077,719 ('085 patent)	06/08/1998	DPCP-Patent-0002018	DPCP-Patent-0002219		
0512	File wrapper for United States Patent Application Serial No. 09/169,231 ('213 patent)	10/09/1998	DPCP-Patent-0002220	DPCP-Patent-0002374		
0514	Declaration of Tommy Anderson from file wrapper for United States Patent Application Serial No. 09/187,277	02/23/2000	AZ-NX-MDL-00799276	AZ-NX-MDL-00799282		Hearsay

Pl Ex	Description	Date	B6DOC	EndDoc	Additional Bites	REVISED OBJECTION
0515	File wrapper for United States Patent Application Serial No. 09/287,945 ('103 patent)	09/01/1999	DPCP-Patent-0002375	DPCP-Patent-0002449		
0516	File wrapper for United States Patent Application Serial No. 09/465,148 ('48 patent)	12/15/1999	DPCP-Patent-0002450	DPCP-Patent-0002506		
0517	File wrapper for United States Patent Application Serial No. 09/485,218 ('810 patent)	02/04/2000	DPCP-Patent-0002507	DPCP-Patent-0002643		
0518	File wrapper for United States Patent Application Serial No. 08/650,044 ('872 patent)	10/16/2000	DPCP-Patent-0002644	DPCP-Patent-0003632		
0519	File wrapper for United States Patent Application Serial No. 10/672,936 ('070 Patent)	09/25/2003	DPCP-Patent-0003633	DPCP-Patent-0004244		
0520	Letter from Ranbaxy Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter) with enclosure	10/14/2005	RAN-ESM0019845	RAN-ESM0019954		
0521	Letter from Ranbaxy to AstraZeneca counsel	11/14/2005	NEX-RBX 3426760	NEX-RBX 3426760	Hearsay; Incomplete	
0522	Letter from MAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	01/23/2006	NEX-RBX 2074653	NEX-RBX 2074613		
0523	Letter from MAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	02/10/2006	NEX-RBX 2074614	NEX-RBX 2074622		
0524	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	08/17/2006	NEX-RBX 2074623	NEX-RBX 2074650		
0525	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	09/08/2006	NEX-RBX 2074651	NEX-RBX 2074678		
0526	Letter from Matrix Laboratories, Ltd. to AstraZeneca (Paragraph IV Letter)	07/24/2007	[no Bates]			
0527	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	12/04/2007	DR1MDL 005963	DR1MDL 006045	Authenticity; Hearsay; Double Hearsay; Relevance	
0528	Letter from Ranbaxy, Inc. to AstraZeneca (Paragraph IV Letter)	08/14/2008	AZ-NX-MDL-012384872	AZ-NX-MDL-00682566	Hearsay	
0529	Letter from Matrix Laboratories, Ltd. to AstraZeneca (Paragraph IV Letter)	08/22/2008	[no Bates]			
0530	Letter from MAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	08/25/2008	AZ-NX-MDL-00682557	AZ-NX-MDL-00682566	Authenticity; Hearsay; Double Hearsay; Relevance; Misleading	
0531	Letter from Sandoz, Inc. to AstraZeneca (Paragraph IV Letter)	12/22/2008	NONPARTY_SANDOZ0021179	NONPARTY_SANDOZ0021179	Hearsay	
0532	Letter from Lupin Ltd. to AstraZeneca (Paragraph IV Letter)	09/08/2009	[no Bates]	21249	Authenticity; Hearsay	
0533	Letter for Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	12/17/2009	AZ-NX-MDL-00909519	AZ-NX-MDL-00909566	Authenticity; Hearsay	
0534	Letter from Hetero Drug Limited Unit III to AstraZeneca (Paragraph IV Letter)	06/17/2011	[no Bates]			Authenticity; Hearsay

IP EVIDENCE	Description	Date	Ber Doc	End Doc	Additional Notes	REVISION LOG
0535	Letter from Torrent Pharmaceuticals Ltd. to AstraZeneca [Paragraph IV Letter]	12/15/2011	[no dates]			Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0536	Letter from Mylan Laboratories Ltd. to AstraZeneca [Paragraph IV Letter]	01/24/2012	[no dates]			Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0537	Letter from Watson Laboratories, Inc. - Florida to AstraZeneca [Paragraph IV Letter]	02/04/2013	[no dates]			Authenticity; Hearsay
0538	Letter from Wockhardt Limited to AstraZeneca [Paragraph IV Letter]	05/28/2013	[no dates]			Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0539	Andersen KK, Tetrahedron Lett. 1962;5:33-5.	undated	[no dates]			Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0542	European patent application EP 0 005 129 A1	10/31/1979	[no dates]			Hearsay
0544	European patent specification EP 0 005 129 B1	04/29/1981	[no dates]			Hearsay
0545	United States Patent No. 4,337,257	06/29/1982	[no dates]			Hearsay
0548	Richter P, Dužatč E, Deshmukh MN, Kagan HB. J Am Chem Soc. 1984;106(26):188-93.	01/01/1984	DPCP-Patent-0004400	DPCP-Patent-0004405		Hearsay
0549	Di Fuira F, Modena G, Seraglia. Synthesis. 1984 Apr;1984:325-6.	04/01/1984	[no dates]			Hearsay
0550	United States Patent No. 4,472,409	09/18/1984	[no dates]			Hearsay
0551	Gugler R, Jensen IC. Gastroenterology. 1985;89(6):1235-1241.	01/01/1985	[no dates]			Hearsay
0552	Kagan HB, Dužatč E, Nemecek C, et al. Pure Appl Chem. 1985;7(12):1911-6. [marked as Plaintiff's Exhibit 159 in No. 05-cv-0553 (D.N.J.)]	01/01/1985	AZ-NK-MDL-00802586	AZ-NK-MDL-00802591		Hearsay
0554	[Society of Japanese Pharmacopoeial]. Iyakuhin seizo shishin [Pharmaceutical manufacturing guidelines]. 1985 ed. Tokyo: [The Pharmaceutical Times Co.]; 1985. Japanese, English.	10/22/1985	[no dates]			Hearsay
0556	Schreiber SL, Schreiber TS, Smith DB, J Am Chem Soc. 1987;109(5):1125-9.	01/01/1987	[no dates]			Hearsay
0557	Sierist-Nelson K, Krasso A, Mäxller RK, Fischl AE. Ro 28-5364, a potent new inhibitor of the gastric (H+ and K+-ATPase. Eur J Biochem. 1987;166:453-9.	01/01/1987	NEX-RBX 0464502	NEX-RBX 0464508		Hearsay
0558	Zhao SH, Samuel O, Kagan HB. Tetrahedron. 1987;43(12):5135-44.	01/01/1987	DR1MDL 199528	DR1MDL 199537		Hearsay
0559	U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Rockville (MD): U.S. Food and Drug Administration; 1987 Feb.	02/01/1987	[no dates]			Hearsay
0560	Smith RL, Caldwell J. Trends Pharmacol Sci. 1988;9(3):75-7.	03/01/1988	[no dates]			Hearsay
0562	Kagan HB, Rebire F, Syrett. 1989;1990(11):543-50.	01/01/1990	DPCP-Patent-0004416-23	DPCP-Patent-0004416-23		Hearsay

Exhibit	Description	Date	Brief Doc	EndDoc	Additional Bates	REVISED OBJECTION
0564	Rengarth CG, Andersen T, Lagerstrom P-O, et al. Ther Drug Monit. 1990;12(2):153-172.	03/01/1990	[no bates]			Hearsay
0565	Andersen T, Rengarth CG, Dahl-Puustinen M, et al. Ther Drug Monit. 1990;12(4):151-6.	07/01/1990	[no bates]			Hearsay
0567	Kromer W, Postius S, Riedel R, et al. J Pharmacol Exp Ther. 1990;254(1):1-29. 35.	07/01/1990	[no bates]			Hearsay
0568	Miwa K, Mitani M, Tsukamoto T, et al. Jpn Pharmacol Ther. 1990;18(9):165-87. English translation.	09/01/1990	[no bates]			Hearsay
0570	Eriksson P, Isaksson R, Lorrentzon P, Lindberg P. J Chromatogr. 1990;532(2):305-319.	11/16/1990	DPCP-Patent-0001811	DPCP-Patent-0001825		Hearsay
0571	Hanauer G, Graf U, Maisner T, Neth Find Exp Clin Pharmacol. 1991;13(1):63-67.	01/01/1991	[no bates]			Hearsay
0573	Simon WA, Buddegen C, Fahr S, et al. Biochem Pharmacol. 1991;42(2):347-51.	07/05/1991	[no bates]			Hearsay
0574	Ariens EJ. Eur J Clin Pharmacol. 1993;41(2):89-93.	08/01/1991	[no bates]			Hearsay
0577	Andersen T, Rengarth CG, Lou YC, et al. Pharmacometrics. 1992;2:25-31.	01/01/1992	[no bates]			Hearsay
0578	Carlson R. Design and optimization in organic synthesis. Amsterdam: Elsevier Science Publishers; 1992. p. 13-15.	01/01/1992	[no bates]			Hearsay
0579	Physicians' Desk Reference: PDR. 46th ed. Montvale (NJ): Medical Economics Co.; 1992. Phillips Delayed-Release Capsules; p. 1530-2.	01/01/1992	[no bates]			Hearsay; Incomplete
0580	Sohn DR, Kobayashi K, Chiba K, et al. J Pharmacol Exp Ther. 1992;262(3):1195-202.	03/01/1992	[no bates]			Hearsay
0582	Food and Drug Administration. Announcement: FDA's policy statement for the development of new stereoisomeric drugs. Chirality. 1992;15(5):338-340.	05/05/1992	[no bates]			Hearsay
0583	German patent application DE 40 35 455 A1.	05/14/1992	[no bates]			Authenticity; Hearsay
0584	German patent application DE 40 35 455 A1. English translation.	05/14/1992	DPCP-Patent-0001728	DPCP-Patent-0001746		Hearsay
0585	57 Fed. Reg. 22,249	05/27/1992	[no bates]			Incomplete
0586	FDA's Policy Statement for the Development of New Stereoisomeric Drugs	05/27/1992	NEX-RBX 2514168	NEX-RBX 2514173		Authenticity; Hearsay
0587	Crom WR. Am J Hosp Pharm. 1992;49 Supp 1:59-514.	09/01/1992	[no bates]			Hearsay; Misleading; Relevance
0588	Astra memorandum by P. Lindberg, A Single Enantiomer of Omeprazole -- A Possible Future Follow-Up to Omeprazole	01/04/1993	AZ-NX-MDL-00750940	AZ-NX-MDL-00750947		Hearsay
						Authenticity; Hearsay; Unfairly Prejudicial

Exhibit	Description	Date	Ref Doc	End Date	Source/Location	REvised/Correction
0589	AstraZeneca memorandum, Omeprazolesomer, with attachments	01/05/1993	NEX-RBX 2524861	NEX-RBX 2524870		
0590	Gross M, Cartwright A, Campbell B, et al. Drug Info J. 1993;27(2):45-57.	04/01/1993	[no Bates]			Double Hearsay; Hearsay; Incomplete
0591	Seller JP. Drug Info J. 1993;27(2):485-9.	04/01/1993	[no Bates]			Hearsay
0598	Astra-Hätsle minutes, Project team Meeting: Omepazole Successors (OS), April 27, 1994.	04/28/1994	NEX-RBX 2058938	NEX-RBX 2058939		Hearsay
0599	Astra document, Omepazole Successors	05/24/1994	AZ-NX-MDL-00749251	AZ-NX-MDL-00749253		Hearsay
0600	Astra Hätsle Report No. 2142-43, A Review of Biological Data for H Elebring	08/17/1994	NEX-RBX 2833963	NEX-RBX 2833978		Authenticity; Hearsay
0602	International patent application WO 94/27988 A1	12/08/1994	[no Bates]			
0603	Byrn S, Pfeiffer R, Ganey M, et al. Review: Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. 1993;12(7):945-54. [marked as Defendants' Exhibit 10.11 in No. 05-cv-05553 (D.N.J.)]	01/01/1995	AZ-NX-MDL-00799752	AZ-NX-MDL-00799761		Hearsay
0604	Cairns AM, Chibou RH, Rogers ID, et al. J Chromatogr B. 1995;656(2):323-8.	01/01/1995	DPCP-Patent-0001470	DPCP-Patent-0001475		Hearsay
0605	United States Patent No. 5,386,032	01/31/1995	[no Bates]			Hearsay
0606	Astra Hätsle project plan. Project No. 836-1-, Omepazole Successor, H 199/18.	02/21/1995	NEX-RBX 2675458	NEX-RBX 2675458		Hearsay
0609	Astra Hätsle minutes, Extended Omepazole Successors meeting, October 20, 1995.	10/26/1995	AZ-NX-MDL-00648906	AZ-NX-MDL-00648909		Hearsay
0610	International patent application WO 95/01623 A1	01/25/1996	[no Bates]			Hearsay
0613	AstraZeneca document, Patent Situation for H 199/18 - An Update 97-02-05 [marked as Defendants' Exhibit 11.5 in No. 05-cv-05553 (D.N.J.)]	02/05/1997	DRIMDL 195122	DRIMDL 195123		Authenticity; Hearsay
0614	United States Patent No. 5,695,818	12/02/1997	[no Bates]			
0617	Byrn SR, Pfeiffer RP, Stowell GS. Solid-state chemistry of drugs. 2nd ed. West Lafayette (IN): SSCI, Inc.; 1999. Chapter 3, The X-Ray Powder Diffraction Method; p. 59-67	01/01/1999	[no Bates]			Hearsay
0619	Perera NA, MacMillan DW, J Am Chem Soc. 2001;123:4370-4371.	01/01/2001	[no Bates]			Hearsay
0620	Yoon TP, MacMillan DW. J Am Chem Soc. 2001;123(12):2911-2.	03/02/2001	[no Bates]			Hearsay
0621	International patent application WO 02/062785 A1	08/15/2002	[no Bates]			Hearsay

Index	Description	Date	Begin Doc	End Doc	Additional Bates	REVISED DOCUMENT
0626	FDA. Guidance For Industry, ANDAs: Pharmaceutical Solid Polymorphism, Chemistry, Manufacturing and Controls Information. Draft. Rockville (MD); FDA; 2004 Dec.	11/23/2004	[no bates]			Hearsay Misleading
0627	69 Fed. Reg. 75,987	12/20/2004	[no bates]			
0628	International patent application WO 2004/111029 A2	12/23/2004	[no bates]			Hearsay
0629	Letter from AstraZeneca to the FDA	03/14/2005	[no bates]			Authenticity; Hearsay
0630	Fujina Y.; Kunaka M.; Inoue T.; Matsumoto I. Org Process Res Dev. 2006;10(5):905-13.	01/01/2006	[no bates]			Hearsay
0635	Raju SV; Purandhar K; Reddy PF, et al. Org Process Res Dev. 2006;10(1):33-5.	01/01/2006	[no bates]			Hearsay Hearsay
0636	Darrow, 2007 Stan. Tech. L. Rev. 2	01/01/2007	[no bates]			Hearsay Hearsay
0637	United States Patent No. 7,169,793	01/30/2007	[no bates]			Hearsay
0638	Cipla document; Esomeprazole Magnesium Dihydrate Delayed Release Capsules [marked as Plaintiffs' Exhibit 212 in No. 05-cv-05553 (D.N.J.)]	02/01/2007	DRIMDL 197400	DRIMDL 197412		Hearsay
0639	FDA. Guidance For Industry, ANDAs: Pharmaceutical Solid Polymorphism, Chemistry, Manufacturing and Controls Information. Rockville (MD); FDA; 2007 Jul.	07/01/2007	[no bates]			
0640	Atkins P, Jones L. Chemical Principles: The Quest for Insight. 4th ed. New York: W.H. Freeman and Co.; 2008. Chapter 18-2, Isomers; p. 734-7.	01/01/2008	[no bates]			
0641	International patent application WO 2008/017020 A2	02/07/2008	[no bates]			Hearsay
0642	2008/045777 A2	04/17/2008	[no bates]			Hearsay
0644	AstraZeneca response document. Replies to questions posed at the meeting between the MEB and AstraZeneca on 29 July 2008 regarding generic applications for esomeprazole. Includes Appendix A: Esomeprazole development and properties.	08/28/2008	AZ-NX-MDL-00669383	AZ-NX-MDL-00669434		Hearsay
0656	Florence AT; Attwood D. Physicochemical principles of pharmacy. 5th ed. London: Pharmaceutical Press; 2011. Figure 1.3. Classification of solids p. 8.	01/01/2011	[no bates]			Hearsay
0660	United States Pharmacopeial Convention. The United States pharmacopeia. The national formulary. USP 35th rev., NF 30th ed. Vol 2. Rockville (MD); The Convention; 2011. Esomeprazole magnesium; p. 3097-9.	11/01/2011	AZ-NX-MDL-01270611	AZ-NX-MDL-01270615		Authenticity; Hearsay

Ref#	Description	Date	Beg Doc#	End Doc#	Additional Notes	REV'D/OBJECTION
0663	Cecere G, König CM, Alleva J., MacMillan DW, J Am Chem Soc. 2013;135:11521-4.	01/01/2013	[no dates]			Hearsay
0665	Pirnat MT, Rankic DA, Martin DB, MacMillan DW, Science. 2013 Mar 29;339(6227):1593-6. Accompanied by: Supplementary Materials in pdf. p. S1-S67.	03/29/2013	[no dates]			
0666	Trotz-11: Opinion, Dkt. 142, No. 11-cv-02317 (D.N.J.)	05/01/2013	DRIMDL 219158	DRIMDL 219177		Hearsay
0672	Thin layer chromatography and color markers, or chromatography for kids, Science Project Lab website. <a href="http://www.scienceprojectlab.com/thin-layer-chromatography-for-kids.html">http://www.scienceprojectlab.com/thin-layer-chromatography-for-kids.html</a> . Accessed on August 22, 2013.	08/22/2013	[no dates]			
0677	Astra presentation, Omeprazole Successors.	undated	NEX-RBX 0376198	NEX-RBX 0575240		Hearsay; Incomplete
0678	AstraZeneca SR# 61399, NEXIUM-History of NEXIUM-HAksie lab notebook pages with translations	undated	NEX-RBX 0500584	NEX-RBX 0500585		Authenticity, Hearsay; Incomplete
0681	undated	[no dates]				Authenticity, Hearsay
0684	Case COMP/A-37/507/F3 - AstraZeneca, Commission Decision Ct2005(1)757	06/15/2005	[no dates]			Authenticity, Hearsay; Relevance; Misleading; Unfair Prejudicial
0685	Case T-321/05, AstraZeneca Ab v. Commn., [2010] 1 C.R. II-2830	07/01/2010	[no dates]			Authenticity, Hearsay; Misleading; Relevance; Unfair Prejudicial
0686	Case C-457/10 P, AstraZeneca Ab v. Comm'n, Judgment	12/06/2012	[no dates]			Authenticity, Hearsay; Misleading; Relevance; Unfair Prejudicial
0688	Development of New Stereosemiconjugates/Information/Guidances/ucm122883.htm	05/01/1992	[no dates]			Authenticity, Hearsay
0689	LegalMetric Courtroom Report. Prevailing Accused Infringers in Patent Cases Where Six or More Patents Were Asserted.	05/01/2013	[no dates]			Hearsay
0690	Andersson T, Cederborg C, Regardh C, G, Stanberg J, Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol. 1990;39(1):95-97.	03/01/1990	[no dates]			
0701	Civil Docket, No. 05-cv-05553 (D.N.J.)	04/11/2013	[no dates]			Hearsay
0702	Complaint, Dkt. 1, No. 05-cv-05553 (D.N.J.)	11/21/2005	Dkt. 1, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0703	Answer, Dkt. 3, No. 05-cv-05553 (D.N.J.)	01/30/2006	Dkt. 3, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0704	Answer to Counterclaim, Dkt. 9, No. 05-cv-05553 (D.N.J.)	02/17/2006	Dkt. 9, No. 05-cv-05553 (D.N.J.)			Relevance
0705	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/17/2006	NEX-RBX 3427274			Hearsay; Relevance
0706	Letter Order, Dkt. 14, No. 05-cv-05553 (D.N.J.)	05/11/2006	Dkt. 14, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance

Date	Description	Date	Revised Date	Additional Dates	End Date
07/09	Order, Dkt. 22, No. 05-cv-05553 (D.N.J.)	09/25/2006	Dkt. 22, No. 05-cv-05553 (D.N.J.)		
0712	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	11/09/2006	NEX-RBX 3426542	NEX-RBX 3426545	Relevance
0713	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	11/17/2006	NEX-RBX 3426550	NEX-RBX 3426550	Hearsay; Relevance
0714	Minutes and transcript of telephone conference, No. 05-cv-05553 (D.N.J.)	11/20/2006	Dkt. 28, No. 05-cv-05553 (D.N.J.)	NEX-RBX 3417234 - NEX-RBX 3417288	Hearsay; Relevance
0717	Pretrial Scheduling Order, Dkt. 29, No. 05-cv-05553 (D.N.J.)	12/01/2006	Dkt. 29, No. 05-cv-05553 (D.N.J.)		Relevance; Misleading
0718	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	12/18/2006	NEX-RBX 3426449	NEX-RBX 3426451	Hearsay; Relevance
0722	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	01/12/2007	NEX-RBX 3426554	NEX-RBX 3426558	Hearsay; Misleading; Relevance
0725	Letter from Astrazeneca to Magistrate Judge Bongiovanni with attached Declaration of Renée Sekino in Support, No. 05-cv-05553 (D.N.J.)	01/21/2007	NEX-RBX 3426482	NEX-RBX 3426487	NEX-RBX 3426494 - NEX-RBX 3426558; NEX-RBX 3426488 - NEX-RBX 3426491
0726	Letter from Rambax counsel and Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	01/26/2007	NEX-RBX 3427186	NEX-RBX 3427187	Relevance
0728	Minutes and transcript of telephone conference, No. 05-cv-05553 (D.N.J.)	03/14/2007	Dkt. 35, No. 05-cv-05553 (D.N.J.)	NEX-RBX 3417289 - NEX-RBX 3417336	Double Hearsay; Hearsay; Relevance
0730	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/11/2007	NEX-RBX 3426560	NEX-RBX 3426583	Relevance; Misleading; Relevance
0731	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/13/2007	NEX-RBX 3426586	NEX-RBX 3426633	Relevance; Misleading; Relevance
0732	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/17/2007	NEX-RBX 3427146	NEX-RBX 3427171	Hearsay; Relevance; Unfairly Prejudicial
0733	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/20/2007	NEX-RBX 3426634	NEX-RBX 3426654	Double Hearsay; Hearsay
0734	Letter from Astrazeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/25/2007	NEX-RBX 3426635	NEX-RBX 3426809	Hearsay
0735	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/26/2007	NEX-RBX 3426810	NEX-RBX 3426828	Hearsay
0737	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/01/2007	NEX-RBX 3426963	NEX-RBX 3426964	Relevance
0738	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/07/2007	Teva-ESO-029812	Teva-ESO-Q29820	Hearsay
0739	Letter from Rambax counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/08/2007	NEX-RBX 3427193	NEX-RBX 3427196	Double Hearsay; Hearsay; Unfairly Prejudicial; Relevance

Ex.	Description	Date	B6 Doc	End Doc	Additional Bases	REVISER OBJECTION
0740	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/11/2007	Teva-ESO-D29821.93		Teva-ESO-D29822.93	
0741	Letter from Rabnay counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/17/2007	NEX-RBX 3427198	NEX-RBX 3427204		Hearsay
0742	Letter Order, Dkt. 39, No. 05-cv-05553 (D.N.J.)	06/27/2007	Dkt. 39, No. 05-cv-05553 (D.N.J.)			Double Hearsay; Hearsay; Relevance
0743	AstraZeneca's Motion for a Letter of Request to Take a Deposition in Germany and Obtain Documents Related to the DE 455 Patent Application, and Memorandum in Support of AstraZeneca's Motion for a Letter of Request to Take a Deposition and Collect Documents in Germany, No. 05-cv-05553 (D.N.J.)	07/02/2007	NEX-RBX 3425967	NEX-RBX 3426567	NEX-RBX 3426979 - NEX-RBX 3426982	Hearsay; Relevance
0744	Ranbaxy's Responses and Objections to AstraZeneca's First Set of Request for Admissions (Nos. 1-554), No. 05-cv-05553 (D.N.J.)	07/16/2007	NEX-RBX 3424279	NEX-RBX 3424630		
0745	Letter from Rabnay counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	07/19/2007	RAN-ESM000244	RAN-ESM000250		Hearsay; Relevance
0746	Letter from AstraZeneca counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	07/22/2007	AZ-NY-MDL-01238466	AZ-NY-MDL-01238471		Hearsay; Relevance
0748	Memorandum of Defendants Ivax Corp., Ivax Pharmaceuticals, Inc., Teva Pharmaceuticals NV, Inc., Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. in Opposition to AstraZeneca's Motion for a Letter of Request to Take a Deposition and Collect Documents in Germany, No. 05-cv-05553 (D.N.J.)	07/23/2007	Dkt. 41, No. 05-cv-05553 (D.N.J.)			
0749	Letter Order, Dkt. 42, No. 05-cv-05553 (D.N.J.)	08/07/2007	Dkt. 42, No. 05-cv-05553 (D.N.J.)			
0752	Letter Order, Dkt. 44, No. 05-cv-05553 (D.N.J.)	08/14/2007	Dkt. 44, No. 05-cv-05553 (D.N.J.)			Double Hearsay; Hearsay
0753	Letter Order, Dkt. 45, No. 05-cv-05553 (D.N.J.)	08/15/2007	Dkt. 45, No. 05-cv-05553 (D.N.J.)			Hearsay
0754	Letter from Rabnay counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	08/15/2007	NEX-RBX 3427018	NEX-RBX 3427019		
0757	Letter from Rabnay counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	08/28/2007	NEX-RBX 3427175	NEX-RBX 3427179		Hearsay; Relevance
0760	AstraZeneca's Supplemental Response to Ranbaxy's First Set of Interrogatories to Plaintiffs (No. 1), No. 05-cv-05553 (D.N.J.)	09/14/2007	NEX-RBX 3423912	NEX-RBX 3423986		Double Hearsay; Hearsay; Relevance

File #	Description	Date	Beg Doc#	End Doc#	Additional facts	REVISED OBJECTION
0765	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni with Proposed Amended Pretrial Scheduling Order, No. 05-cv-05553 (D.N.J.)	10/05/2007	NEX-RBX 3427142		NEX-RBX 3427145	
0766	Amended Pretrial Scheduling Order, Dkt. 56, No. 05-cv-05553 (D.N.J.)	10/09/2007	Dkt. 58, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0767	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/09/2007	NEX-RBX 3427022		NEX-RBX 3427028	
0768	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/10/2007	NEX-RBX 3427173		NEX-RBX 3427184	
0770	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/24/2007	NEX-RBX 3427029		NEX-RBX 3427030	
0772	Ranbaxy's Responses to AstraZeneca's First Set of Contentions Interrogatories (Nos. 1-3), No. 05-cv-05553 (D.N.J.)	11/30/2007	NEX-RBX 3423878		NEX-RBX 3423886	
0773	AstraZeneca's Response to Ranbaxy's Second Set of Requests for Admissions to Plaintiffs (Nos. 142-158), No. 05-cv-05553 (D.N.J.)	12/17/2007	NEX-RBX 3424771		NEX-RBX 3424779	
0774	Order, Dkt. 68, No. 05-cv-05553 (D.N.J.)	01/15/2008	Dkt. 68, No. 05-cv-05553 (D.N.J.)			Hearsay
0775	Letter Order, Dkt. 72, No. 05-cv-05553 (D.N.J.)	01/29/2008	Dkt. 72, No. 05-cv-05553 (D.N.J.)			Double Hearsay; Hearsay; Relevance
0776	Memorandum Opinion and Order Issued in Conjunction with the Court's Request for International Judicial Assistance Pursuant to the Hague Convention of 18 March 1970 on the Taking of Evidence in Civil or Commercial Matters to the Appropriate Judicial Authority in Sweden, Dkt. 73, No. 05-cv-05553 (D.N.J.)	01/29/2008	Dkt. 73, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0777	Order, Dkt. 76 (sealed), No. 05-cv-0553 (D.N.J.)	02/01/2008	NEX-RBX 3417341		NEX-RBX 3417343	
0779	Transcript of hearing, No. 05-cv-0553 (D.N.J.)	04/14/2008	NEX-RBX 0000435		NEX-RBX 0000440	
0780	Consent Judgment, Dkt. 80, No. 05-cv-0553 (D.N.J.)	04/14/2008	Dkt. 80, No. 05-cv-05553 (D.N.J.)			Hearsay
0781	Rule 2006 Summary of AstraZeneca Litigation with Ranbaxy	01/23/2014	[no bates]			Cumulative; Double Hearsay; hearsay; incomplete; misleading; Not a proper summary under Rule 1006; Unfairly Prejudicial
0782	Civil Docket, No. 05-cv-01057 (D.N.J.)	04/11/2013	[no bates]			
0783	Civil Docket, No. 08-cv-02165 (D.N.J.)	04/11/2013	[no bates]			
0784	Civil Docket, No. 08-cv-01993 (D.N.J.)	04/11/2013	[no bates]			
0785	Complaint, Dkt. 1, No. 06-cv-01057 (D.N.J.)	03/08/2006	Dkt. 1, No. 06-cv-01057 (D.N.J.)			
0786	Answer of VAX Corporation, Dkt. 13, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 13, No. 06-cv-01057 (D.N.J.)			No. 06-cv-01057 (D.N.J.)

Ex.	Description	Date	Beg Doc#	End Doc#	Additional Bates	Revised objection
0787	Answer of IVAX Pharmaceuticals, Inc., Dkt. 14, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 14, No. 06-cv-01057 (D.N.J.)			
0788	Answer of Teva Pharmaceuticals USA, Inc., Dkt. 15, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 15, No. 06-cv-01057 (D.N.J.)			
0789	Answer of IVAX Pharmaceuticals, Inc., Dkt. 16, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 16, No. 06-cv-01057 (D.N.J.)			
0794	Letter Order, Dkt. 32, No. 06-cv-01057 (D.N.J.)	08/07/2006	Dkt. 32, No. 06-cv-01057 (D.N.J.)			
0796	Letter from AstraZeneca counsel to Judge Pisano, No. 06-cv-01057 (D.N.J.)	08/11/2006	NEX-RBX 3426330	NEX-RBX 3426340		Hearsay
0797	Letter from Teva counsel to Judge Pisano, No. 06-cv-01057 (D.N.J.)	08/11/2006	Teva-ESO-067328	Teva-ESO-067331		Hearsay
0798	Order, Dkt. 49, No. 06-cv-01057 (D.N.J.)	09/25/2006	Dkt. 49, No. 06-cv-01057 (D.N.J.)			Hearsay
0809	Defendants' Response to Plaintiffs' First Set of Requests for Admission to Teva/IVAX (Nos. 1-303); No. 05-cv-05553 (D.N.J.)	07/16/2007	NEX-RBX 3424154	NEX-RBX 3424278		
0817	AstraZeneca's Supplemental Response to Defendants' (Teva's) First Set of Interrogatories to Plaintiffs (No. 1, No. 05-cv-05553 (D.N.J.)	09/14/2007	NEX-RBX 3424006	NEX-RBX 3424061		Hearsay
0820	Notice of Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, with Memorandum in Support and Declaration of Nicole Corona, No. 05-cv-05553 (D.N.J.)	10/19/2007	Dkt. 59, No. 05-cv-05553 (D.N.J.)			Teva-ESO-031842 - Teva-ESO-031859; Teva-ESO-031837 - Teva-ESO-031839
0821	Defendant's Teva/IVAX's Opposition to Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, with Declaration of Michael E. Patunis in Support, Dkt. 63, No. 05-cv-05553 (D.N.J.)	11/05/2007	Teva-ESO-018409	Teva-ESO-018459		Hearsay
0824	Order, Dkt. 79, No. 05-cv-05553 (D.N.J.)	03/31/2008	Dkt. 79, No. 05-cv-05553 (D.N.J.)			Relevance
0825	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/23/2008	NEX-RBX 3427084	NEX-RBX 3427086		Hearsay
0827	Letter from DRG counsel to Magistrate Judge Bongiovanni, Nos. 05-cv-05553 (D.N.J.) and 08-cv-00328 (D.N.J.)	04/25/2008	NEX-RBX 3426306	NEX-RBX 3426308		Hearsay
0828	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/25/2008	NEX-RBX 3427091	NEX-RBX 3427092		
0829	Complaint, Dkt. 1, No. 08-cv-02165 (D.N.J.)	04/30/2008	Dkt. 1, No. 08-cv-02165 (D.N.J.)			
0832	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/02/2008	NEX-RBX 3427100	NEX-RBX 3427110		

SPK#	Description	Date	Ref Doc	End Date	Additional Dates	REVISED ORIGINATOR
0833	Letter from DRl counsel to Magistrate Judge Bongiovanni, Nos. 05-cv-05553 (D.N.J.) and 08-cv-0328 (D.N.J.)	05/07/2008	NEX-RBX 3426310		NEX-RBX 3426312	
0838	Letter Order, Dkt. 82, No. 05-cv-05553 (D.N.J.)	05/28/2008	Dkt. 82, No. 05-cv-05553 (D.N.J.)			Hearsay
0839	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	06/04/2008	NEX-RBX 3426321	NEX-RBX 3426323		Hearsay
0841	Defendants Teva/IVAX's Supplemental Opposition to Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, Dkt. 84, No. 05-cv-05553 (D.N.J.)	06/16/2008	Dkt. 84, No. 05-cv-05553 (D.N.J.)			Hearsay
0843	Defendants Teva/IVAX's Opposition to Plaintiff AstraZeneca's Motion to Strike Teva/IVAX's Supplemental Opposition, Dkt. 82, No. 05-cv-05553 (D.N.J.)	07/07/2008	Dkt. 92, No. 05-cv-05553 (D.N.J.)			Hearsay
0844	Notice of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively For a Stay, Memorandum in Support, (Proposed) Order Granting Defendants' Motion, and Declaration of Anna Brook, Dkt. 8, No. 08-cv-02165 (D.N.J.)	07/08/2008	Dkt. 8, No. 08-cv-02165 (D.N.J.)			Hearsay
0845	Reply Memorandum on AstraZeneca's Motion to Strike Teva's Improper Sur-Reply or Alternatively for Leave to File a Substantive Submission, Dkt. 94, No. 05-cv-05553 (D.N.J.)	07/14/2008	Dkt. 94, No. 05-cv-05553 (D.N.J.)			Hearsay
0846	Plaintiff IVAX Pharmaceuticals, Inc.'s Opposition to Defendants' Motion under Fed. R. Civ. P. 12(b)(1) to Dismiss for Lack of Subject Matter Jurisdiction, with Declaration of Michael E. Pastura, Dkt. 15, No. 08-cv-02165 (D.N.J.)	08/05/2008	Dkt. 15, No. 08-cv-02165 (D.N.J.)			Hearsay
0847	Reply Memorandum in Support of Defendants 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Dkt. 17, No. 08-cv-02165 (D.N.J.)	08/11/2008	Dkt. 17, No. 08-cv-02165 (D.N.J.)			Hearsay
0848	Opinion and Order, Dkt. 18 and 19, No. 08-cv-02165 (D.N.J.)	08/28/2008	Dkt. 18 and 19, No. 08-cv-02165 (D.N.J.)			Hearsay
0849	Letter from DRl counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.) and No. 08-cv-00328 (D.N.J.)	09/05/2008	DRIMDL 203390	DRIMDL 203391		Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0851	Minutes and transcript of hearing, No. 05-cv-05553 and No. 08-cv-00328 (D.N.J.)	09/09/2008	Dkt. 97, No. 05-cv-05553 (D.N.J.)	DRIMDL 191742 - DRIMDL 191821		Hearsay

Plk#	Description	Date	DefDate	BegDate	EndDate	Additional Bates#	REVISED OBJECTION
0853	Letter from Teva counsel to Judge Pisano, Dkt. 20, No. 08-cv-02165 (D.N.J.)	09/12/2008	Dkt. 20, No. 08-cv-02165 (D.N.J.)				Hearsay
0855	Complaint, Dkt. 1, No. 08-cv-04993 (D.N.J.)	10/09/2008	Dkt. 1, No. 08-cv-04993 (D.N.J.)				
0856	Letter from Teva counsel to Judge Pisano, Dkt. 21, No. 08-cv-02165 (D.N.J.)	10/09/2008	Dkt. 21, No. 08-cv-02165 (D.N.J.)				Hearsay
0861	Answer, Dkt. 8, No. 08-cv-04993 (D.N.J.)	11/13/2008	Dkt. 8, No. 08-cv-04993 (D.N.J.)				Hearsay
0863	Letter from Teva counsel to Judge Pisano, No. 08-cv-02165 (D.N.J.)	11/24/2008	DRLMDL 209022	DRLMDL 209022			Hearsay; Relevance
0867	Memorandum Opinion and Order, Dkt. 103 and 104, No. 08-cv-05553 (D.N.J.)	12/16/2008	Dkt. 103 and 104, No. 08-cv-05553 (D.N.J.)				
0868	Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	12/17/2008	DRLMDL 180178	DRLMDL 180218			Foundation
0869	Amended Complaint, Dkt. 106, No. 08-cv-05553 (D.N.J.)	12/18/2008	Dkt. 106, No. 08-cv-05553 (D.N.J.)				
0872	Answer of Cipla Ltd., Dkt. 22, No. 08-cv-04993 (D.N.J.)	01/08/2009	Dkt. 22, No. 08-cv-04993 (D.N.J.)				Hearsay
0873	Letter from Teva counsel to Judge Pisano, Dkt. 33, No. 08-cv-02165 (D.N.J.)	01/15/2009	Dkt. 33, No. 08-cv-02165 (D.N.J.)				Hearsay
0874	Transcript of case management conference, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	01/16/2009	Teva-ESO-069462	Teva-ESO-069498			Hearsay
0875	Answer to Amended Complaint, Dkt. 112, No. 08-cv-05553 (D.N.J.)	01/23/2009	Dkt. 112, No. 08-cv-05553 (D.N.J.)				Authenticity; Hearsay; Unfairly Prejudicial
0876	Joint letter to Magistrate Judge Bongiovanni, No. 08-cv-05553 (D.N.J.)	01/23/2009	DRLMDL 209070	DRLMDL 209073			Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0877	Letter Order, Dkt. 114, No. 08-cv-05553 (D.N.J.)	01/27/2009	Dkt. 114, No. 08-cv-05553 (D.N.J.)				Hearsay
0878	Answer of Cipla Ltd., Dkt. 115, No. 08-cv-05553 (D.N.J.)	01/27/2009	Dkt. 115, No. 08-cv-05553 (D.N.J.)				Hearsay
0879	Order, Dkt. 38, No. 08-cv-02165 (D.N.J.)	02/13/2009	Dkt. 38, No. 08-cv-02165 (D.N.J.)				Hearsay
0881	Letter from Teva counsel to Judge Pisano, Dkt. 40, No. 08-cv-02165 (D.N.J.)	02/15/2009	Dkt. 40, No. 08-cv-02165 (D.N.J.)				Hearsay
0882	Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	02/20/2009	DRLMDL 180258	DRLMDL 180260			
0883	Order, Dkt. 43, No. 08-cv-02165 (D.N.J.)	02/24/2009	Dkt. 43, No. 08-cv-02165 (D.N.J.)				
0884	Answer, Dkt. 44, No. 08-cv-02165 (D.N.J.)	02/27/2009	Dkt. 44, No. 08-cv-02165 (D.N.J.)				
0885	Plaintiff IVAX Pharmaceuticals, Inc.'s Invalidity Contentions Pursuant to L. Pat. R. 3.5(b), No. 08-cv-02165 (D.N.J.)	03/02/2009	Teva-ESO-108440	Teva-ESO-108473			
0886	Answer to Defendants' Counterclaim, Dkt. 119, No. 08-cv-05553 (D.N.J.)	03/04/2009	Dkt. 119, No. 08-cv-05553 (D.N.J.)				
0887	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 08-cv-000328 (D.N.J.)	03/20/2009	DRLMDL 203861	DRLMDL 203865			Hearsay; Relevance

SPK#	Description	Date	Entered Doc.	Additional Date	REvised Objection
0888	Order, Dkt. 120, No. 05-cv-05553 (D.N.J.)	03/24/2009	DRLMDL 181192	DRLMDL 181193	Hearsay
0889	Letter from DRl. counsel to the Court, Dkt. 121, No. 05-cv-05553 (D.N.J.)	03/25/2009	[no Bates]		
0894	Defendants' Disclosure of Asserted Claims and Infringement Contentions, No. 05-cv-02165	04/16/2009	Teva-ESO-033981	Teva-ESO-034056	Authenticity; Double Hearsay; Collateral Issue; Relevance
0896	Letter from DRl. counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/21/2009	DRLMDL 204149	DRLMDL 204166	Hearsay
0899	Teva/IVAX's Supplemental Response to AstraZeneca's First Set of Contentions Interrogatories to Defendant Teva Corporation, No. 05-cv-05553 (D.N.J.)	04/24/2009	AZ-NX-MDL-00807527	AZ-NX-MDL-00807636	Authenticity; Double Hearsay; Hearsay; Misleading; Relevance; Unfair Prejudicial
0900	Letter from Teva counsel to Judge Piscans, Dkt. 133, No. 05-cv-05553 (D.N.J.)	04/24/2009	Dkt. 133, No. 05-cv-05553 (D.N.J.)	Dkt. 133, No. 05-cv-05553 (D.N.J.)	Hearsay
0901	Amended Scheduling Order, Dkt. 134, No. 05-cv-05553 (D.N.J.)	04/27/2009	Dkt. 134, No. 05-cv-05553 (D.N.J.)	Dkt. 134, No. 05-cv-05553 (D.N.J.)	
0903	Letter from DRl. counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/28/2009	DRLMDL 204240	DRLMDL 204241	
0909	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/01/2009	DRLMDL 204265	DRLMDL 204265	Authenticity; Double Hearsay; Hearsay; Misleading; Relevance; Unfair Prejudicial
0913	AstraZeneca's Second Supplemental Responses and Objections to Defendants' (Teva's) First Set of Interrogatories to Plaintiffs (Nos. 1-5), No. 05-cv-05553 (D.N.J.)	05/04/2009	AZ-NX-MDL-00807174	AZ-NX-MDL-00807351	
0914	Defendant Cipolla's Responses to AstraZeneca's First Set of Interrogatories to Defendant Teva/Cipolla (Nos. 1-3), No. 05-cv-05553 (D.N.J.)	05/04/2009	AZ-NX-MDL-00807637	AZ-NX-MDL-00807644	
0925	Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	05/18/2009	DRLMDL 192163	DRLMDL 192389	
0929	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/22/2009	DRLMDL 185068	DRLMDL 185478	DRLMDL 182675 - DRLMDL 182774
0931	Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Opening Claim Construction Brief, with Declaration of Kenneth E. Crewell in Support, No. 05-cv-05553 (D.N.J.)	05/29/2009	DRLMDL 182012	DRLMDL 182041	Double Hearsay; Hearsay; Misleading; Relevance; Unfair Prejudicial
0933	Defendants Teva/IVAX and Cipolla's Opening Claim Construction Brief, with Certification of Hany W. Rizkalla in Support, No. 05-cv-05553 (D.N.J.)	05/29/2009	DRLMDL 182042	DRLMDL 182076	DRLMDL 188651 - DRLMDL 187258
0952	DRl's Claim Construction Reply Brief, with Declaration of Kenneth E. Crewell in Support, No. 05-cv-05553 (D.N.J.)	06/26/2009	DRLMDL 194601	DRLMDL 199677	Hearsay
					Hearsay

Index	Description	Date	DRIMDL Doc#	DRIMDL Doc#	DRIMDL Doc#	Additional Bates	REvised/objection
0954	Defendants Teva/IYAX and Ciplig's Reply Claim Construction Brief, with Certification of Harry K. Rikella in Support, No. 05-cv-05533 (D.N.J.)	06/26/2009	DRIMDL 200077	DRIMDL 200111	AZ-NX-MDL-00816789 - AZ-NX-MDL 00816894	AZ-NX-MDL-00816789 - AZ-NX-MDL 00816894	
0955	Joint Claim Construction and Prehearing Statement, No. 05-cv-05533 (D.N.J.)	07/02/2009	AZ-NX-MDL-00817633	AZ-NX-MDL-00817630	AZ-NX-MDL-00817274 - AZ-NX-MDL 00817632	AZ-NX-MDL-00817274 - AZ-NX-MDL 00817632	Hearsay
0956	Minutes and transcript of proceedings, 05-cv-05533 (D.N.J.)	07/13/2009	Dkt. 201, No. 05-cv-05533 (D.N.J.)	Dkt. 201, No. 05-cv-05533 (D.N.J.)	DRIMDL 192408 - DRIMDL 192429	DRIMDL 192408 - DRIMDL 192429	
0957	Letter from Astrazeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05533 (D.N.J.)	08/21/2009	DRIMDL 209544	DRIMDL 209544			
0958	Letter from Astrazeneca counsel to Judge Pisano, Dkt. 208, No. 05-cv-05533 (D.N.J.)	09/02/2009	Dkt. 208, No. 05-cv-05533 (D.N.J.)	Dkt. 208, No. 05-cv-05533 (D.N.J.)			Hearsay
0959	Letter Order, Dkt. 209, No. 05-cv-05533 (D.N.J.)	09/03/2009	Dkt. 209, No. 05-cv-05533 (D.N.J.)	Dkt. 209, No. 05-cv-05533 (D.N.J.)			Hearsay
0960	Letter from Teva counsel to Judge Pisano, Dkt. 210, No. 05-cv-05533 (D.N.J.)	09/21/2009	Dkt. 210, No. 05-cv-05533 (D.N.J.)	Dkt. 210, No. 05-cv-05533 (D.N.J.)			Hearsay
0961	Letter from DR! counsel to Magistrate Judge Bongiovanni, No. 08-cv-02165 (D.N.J.) and No. 08-cv-02496 (D.N.J.)	10/19/2009	DRIMDL 216361	DRIMDL 216362			Hearsay
0962	Letter from DR! counsel to Magistrate Judge Bongiovanni, No. 08-cv-02165 (D.N.J.) and No. 08-cv-02496 (D.N.J.)	10/21/2009	DRIMDL 204641	DRIMDL 204642			Double Hearsay; Hearsay
0963	Consent Judgment, Dkt. 213, No. 05-cv-05533 (D.N.J.)	01/07/2010	Dkt. 213, No. 05-cv-05533 (D.N.J.)	Dkt. 213, No. 05-cv-05533 (D.N.J.)			
0964	Rule 1006 Summary of Astrazeneca Litigation with Teva	01/23/2014	[no bates]	[no bates]			Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006
0965	Civil Docket, No. 08-cv-00328 (D.N.J.)	04/11/2013	[no bates]	[no bates]			
0966	Complaint, Dkt. 1, No. 08-cv-00328 (D.N.J.)	01/17/2008	Dkt. 1, No. 08-cv-00328 (D.N.J.)	Dkt. 1, No. 08-cv-00328 (D.N.J.)			
0967	Answer and Counterclaims, Dkt. 3, No. 08-cv-00328 (D.N.J.)	02/12/2008	Dkt. 3, No. 08-cv-00328 (D.N.J.)	Dkt. 3, No. 08-cv-00328 (D.N.J.)			
0968	Letter from DR! counsel to the Court, No. 08-cv-00328 (D.N.J.)	02/12/2008	NEX-RBX 3427056	NEX-RBX 3427059			Hearsay; Double Hearsay; Collateral issue; Relevance
0969	Answer to Counterclaim, Dkt. 13, No. 08-cv-00328 (D.N.J.)	03/05/2008	Dkt. 13, No. 08-cv-00328 (D.N.J.)	Dkt. 13, No. 08-cv-00328 (D.N.J.)			Hearsay
0970	Joint letter to Magistrate Judge Bongiovanni, No. 08-cv-00328 (D.N.J.)	03/18/2008	NEX-RBX 3427056	NEX-RBX 3427053			Hearsay
0971	Preliminary Scheduling Order, Dkt. 14, No. 08-cv-02496 (D.N.J.)	04/03/2008	Dkt. 14, No. 08-cv-02496 (D.N.J.)	Dkt. 14, No. 08-cv-02496 (D.N.J.)			Hearsay
0972	Complaint, Dkt. 1, No. 08-cv-02496 (D.N.J.)	05/13/2008	Dkt. 1, No. 08-cv-02496 (D.N.J.)	Dkt. 1, No. 08-cv-02496 (D.N.J.)			Hearsay
0973	Notice of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Memorandum in Support and Declaration of Anna Brook, Dkt. 6, No. 08-cv-02496 (D.N.J.)	07/08/2008	Dkt. 6, No. 08-cv-02496 (D.N.J.)	Dkt. 6, No. 08-cv-02496 (D.N.J.)			Hearsay

PLK#	Description	Date	Beg Doc	End Doc	Additional Docs	REvised Objection
0979	DRL's Objections and Responses to AstraZeneca's First Set of Contentions Interrogatories to Defendants (Nos. 1-3), No. 08-cv-02328 (D.N.J.)	07/21/2008	AZ-NX-MDL-00807401	AZ-NX-MDL-00807442		
0981	DRL's Memorandum of Law in Opposition to Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, with Affidavit of Alan H. Pollack, Dkt. 11 and 12, No. 08-cv-02496 (D.N.J.)	08/04/2008	Dkt. 11 and 12 , No. 08-cv-02496 (D.N.J.)			
0982	Reply Memorandum in Support of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Dkt. 13, No. 08-cv-02496 (D.N.J.)	08/11/2008	Dkt. 13, No. 08-cv-02496 (D.N.J.)			Hearsay; Unfairly Prejudicial
0983	Opinion and Order, Dkt. 14 and 15, No. 08-cv-02496 (D.N.J.)	08/28/2008	Dkt. 14 and 15, No. 08-cv-02496 (D.N.J.)			Hearsay
0985	Letter from DRL counsel to Judge Pisano attaching DRL's Notice of Motion for Reconsideration of the Court's August 28, 2008 Decision and Order; Proposed Order Granting DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order and Reopening and Reinstating This Action; and DRL's Memorandum of Law in Support of Its Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, No. 08-cv-02496 (D.N.J.)	09/12/2008	DRIMDL 212740	DRIMDL 212760		Hearsay
0989	Defendant AstraZeneca's Opposition to DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, Dkt. 23, No. 08-cv-02496 (D.N.J.)	10/06/2008	Dkt. 23, No. 08-cv-02496 (D.N.J.)			Foundation
0990	DRL's Reply to Defendant AstraZeneca's Opposition to DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, Dkt. 24, No. 08-cv-02496 (D.N.J.)	10/14/2008	Dkt. 24, No. 08-cv-02496 (D.N.J.)			Hearsay
0993	Declaratory Judgment Plaintiffs Non-Infringement Contentions Respecting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	01/26/2009	DRIMDL 218255	DRIMDL 218291		
0994	Letter from DRL counsel to Judge Pisano, Dkt. 37, No. 08-cv-02496 (D.N.J.)	02/19/2009	Dkt. 37 , No. 08-cv-02496 (D.N.J.)			
0995	Order, Dkt. 41, No. 08-cv-02496 (D.N.J.)	02/24/2009	Dkt. 41, No. 08-cv-02496 (D.N.J.)			Hearsay; Relevance; Unfairly Prejudicial
0996	Answer, Dkt. 42, No. 08-cv-02496 (D.N.J.)	02/27/2009	Dkt. 42, No. 08-cv-02496 (D.N.J.)			

Date Entered	Description	Date	Entered Date	Entered By	Additional Notes	Revised by
0997	Declaratory Judgment Plaintiffs' Non-Infringement Contentions Requesting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	03/02/2009	DRLMDL 218292		DRLMDL 218328	
0998	Declaratory Judgment Plaintiffs' Invalidity Contentions Requesting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	03/02/2009	DRLMDL 218329		DRLMDL 218372	
0999	Letter from DRL counsel to Judge Pisano, Dkt. 28, No. 08-cv-0328 (D.N.J.)	03/20/2009	Dkt. 28, No. 08-cv-0328 (D.N.J.)			
1001	AstraZeneca's Responses and Objections to DRL's Second Set of Interrogatories (Nos. 2-5), No. 05-cv-0553 (D.N.J.)	04/13/2009	DRLMDL 183413		DRLMDL 183588	Hearsay
1003	DRL's Responses to AstraZeneca's First Set of Requests for Admissions (1-364), No. 05-cv-0553 (D.N.J.)	05/04/2009	DRLMDL 184419		DRLMDL 184603	Hearsay
1005	DRL's Responses to AstraZeneca's Second Set of Interrogatories (4-5), No. 05-cv-0553 (D.N.J.)	05/06/2009	DRLMDL 209237		DRLMDL 209252	
1013	Letter from DRL counsel to Magistrate Judge Bonaventure, No. 05-cv-0553 (D.N.J.)	09/09/2009	DRLMDL 204552		DRLMDL 204556	
1017	Minutes and transcript of proceedings, No. 05-cv-0553 (D.N.J.)	01/15/2010	Dkt. 214, No. 05-cv-0553 (D.N.J.)		DRLMDL 192142 - DRLMDL 192164	Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
1019	Letter from DRL counsel to AstraZeneca counsel, No. 05-cv-0553 (D.N.J.)	01/20/2010	DRLMDL 209700		DRLMDL 209704	Incomplete
1021	Letter from DRL counsel to Judge Pisano, No. 05-cv-0553 (D.N.J.)	01/21/2010	DRLMDL 209706		DRLMDL 209746	
1023	Minutes and transcript of proceedings, No. 05-cv-0553 (D.N.J.)	01/22/2010	Dkt. 215, No. 05-cv-0553 (D.N.J.)		DRLMDL 192166 - DRLMDL 192192	Hearsay
1025	Letter from DRL counsel to Judge Pisano, No. 05-cv-0553 (D.N.J.)	02/03/2010	DRLMDL 209792		DRLMDL 209810	
1027	E-mail from DRL counsel to Judge Pisano, No. 05-cv-0553 (D.N.J.)	02/04/2010	DRLMDL 209833		DRLMDL 209836	Double Hearsay; Hearsay; Unfairly Prejudicial
1028	Judgment Regarding AstraZeneca's Third Claim for Relief and Dismissing DRL's Second Counterclaim, Dkt. 225, No. 05-cv-0553 (D.N.J.)	02/05/2010	Dkt. 216, No. 05-cv-0553 (D.N.J.)			Hearsay
1030	Notice of AstraZeneca's Motion for Partial Summary Judgment on DRL's Infringement of U.S. Patent No. 6,875,872, with Declaration of Anna Brook, Memorandum in Support, and Proposed Order, No. 05-cv-0553 (D.N.J.)	03/03/2010	Dkt. 219, No. 05-cv-0553 (D.N.J.)		DRLMDL 211127 - DRLMDL 211127; AZ-NX-NB-00890981 - AZ-NX-MOL-00895105; DRLMDL 211159 - DRLMDL 211164; DRLMDL 211222 - DRLMDL 211224	

Pl.Ex.	Description	Date	Bug#	EndDoc	Additional Docket	REvised/objection
1032	Notice of Dr. Reddy's laboratories' Motion for Summary Judgment of Non-Infringement of U.S. Patent Nos. 6,191,148 and 6,428,810 Pursuant to Counts V and VI of its Declaratory Judgment Action, with Memorandum of Law in Support, Statement of Undisputed Facts, Declaration of Dmitry Shehoff, and [Proposed] Judgments, Dkt. 50, No. 08-cv-02496 (D.N.J.)	03/09/2010	DRIMDL 217507	DRIMDL 217509	DRIMDL 217521 - DRIMDL 217528; DRIMDL 217660 - DRIMDL 217663; DRIMDL 217530 - DRIMDL 217512; DRIMDL 217529 - DRIMDL 217552; DRIMDL 217558 - DRIMDL 217649; DRIMDL 217554 - DRIMDL 217557; DRIMDL 217650 - DRIMDL 217655	
1034	Notice of AstraZeneca's Motion to Stay the Case and for an Extension of AstraZeneca's Time to Oppose DRIL's Summary Judgment Motion, with Memorandum in Support, Declaration of Diana Wair and [Proposed Order], Dkt. 58, No. 08-cv-02496 (D.N.J.) Letter from DRIL counsel to Judge Pisano, No. 05-cv-02496 (D.N.J.)	03/19/2010	Dkt. 58, No. 08-cv-02496 (D.N.J.)	DRIMDL 211354 - DRIMDL 211396		Double Hearsay; Hearsay
1036	Letter from DRIL counsel to Judge Pisano, No. 05-cv-02496 (D.N.J.)	03/23/2010	DRIMDL 209878	DRIMDL 209879		Hearsay
1037	Minutes and transcript of Markman hearing, No. 05-cv-02496 (D.N.J.)	03/24/2010	Dkt. 225, No. 05-cv-05553 (D.N.J.)	DRIMDL 192216 - DRIMDL 192337		Hearsay
1040	DRIL's Memorandum of Law in Opposition to AstraZeneca's Motion to Stay the Case and for an Extension of Time to Oppose DRIL's Summary Judgment Motion, Dkt. 64, No. 08-cv-02496 (D.N.J.)	04/05/2010	Dkt. 64, No. 08-cv-02496 (D.N.J.)			
1041	Motion for Summary Judgment of Non-Infringement of U.S. Patent Nos. 6,191,148 and 6,428,810 Pursuant to Counts V and VI of its Declaratory Judgment Action, with Counter-Statement of Facts, Dkt. 65, No. 08-cv-02496 (D.N.J.)	04/05/2010	Dkt. 65, No. 08-cv-02496 (D.N.J.)			Hearsay; Relevance; Unfair Prejudice
1042	Letter from DRIL counsel to Judge Pisano, Dkt. 230, No. 05-cv-05553 (D.N.J.)	04/09/2010	Dkt. 230, No. 05-cv-05553 (D.N.J.)			Hearsay
1044	Reply Memorandum in Support of AstraZeneca's Motion to Stay the Case, with Declaration of Emily Jayne Kunz, Dkt. 58, No. 08-cv-02496 (D.N.J.)	04/12/2010	Dkt. 58, No. 08-cv-02496 (D.N.J.)			Hearsay
1047	Letter from DRIL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/21/2010	DRIMDL 204921	DRIMDL 204922		Hearsay
1049	Letter from DRIL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/26/2010	DRIMDL 205147	DRIMDL 205153		Double Hearsay; Hearsay; Misleading; Relevance; Unfair Prejudice
1050	Letter from AstraZeneca counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/29/2010	DRIMDL 205165	DRIMDL 205200		Hearsay; Relevance
1051	Letter from DRIL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/30/2010	DRIMDL 205202	DRIMDL 205204		Double Hearsay; Hearsay; Misleading; Relevance; Unfair Prejudice
1052	Order sealed, No. 05-cv-05553 (D.N.J.)	05/06/2010	DRIMDL 181429	DRIMDL 181431		

RECEIVED	Description	Date	B6 Doc#	DR/MDL Additional Doc#	REVISED/AMENDED
1053	Transcript of proceedings, No. 05-cv-05553 (D.N.J.)	05/06/2010	DR/MDL 192346	DR/MDL 192362	
1055	Opinion and Order, Dkt. 246 and 247, No. 05-cv-05553 (D.N.J.)	05/18/2010	Dkt. 246 and 247, No. 05-cv-05553 (D.N.J.)		
1057	DR/L's Supplemental Responses to AstraZeneca's Requests for Admissions Nos. 325-364, No. 05-cv-05553 (D.N.J.)	05/21/2010	DR/MDL 209395	DR/MDL 210031	
1059	Letter from DR/L counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	05/21/2010	DR/MDL 210042	DR/MDL 210061	Double Hearsay; Hearsay; Unfairly Prejudicial
1061	Transcript of proceedings, No. 05-cv-05553 (D.N.J.)	06/03/2010	DR/MDL 192390	DR/MDL 192407	
1064	Order, Dkt. 265, No. 05-cv-05553	07/12/2010	Dkt. 255, No. 05-cv-05553 (D.N.J.)		
1071	Transcript of Proceedings, No. 05-cv-05553 (D.N.J.)	10/06/2010	DR/MDL 192026	DR/MDL 192046	
1073	Letter from DR/L counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	10/19/2010	DR/MDL 210144	DR/MDL 210190	Double Hearsay; Hearsay; Misleading; Unfairly Prejudicial
1081	Letter from DR/L counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	11/12/2010	DR/MDL 208498	DR/MDL 208628	Foundation
1084	Letter from DR/L counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	11/24/2010	DR/MDL 208629	DR/MDL 208647	Double Hearsay; Hearsay; Unfairly Prejudicial
1086	Minutes and transcript of proceedings, No. 05-cv-05553 (D.N.J.)	12/21/2010	Dkt. 293, No. 05-cv-05553 (D.N.J.)		DR/MDL 192076 - DR/MDL 192104
1093	Letter from AstraZeneca counsel to Judge Pisano, Dkt. 295, No. 05-cv-05553 (D.N.J.)	01/25/2011	Dkt. 295, No. 05-cv-05553 (D.N.J.)		Hearsay
1094	Consent Judgment, Dkt. 296, No. 05-cv-05553 (D.N.J.)	01/28/2011	Dkt. 296, No. 05-cv-05553 (D.N.J.)		
1095	Rule 1006 Summary of AstraZeneca Litigation with DR/L	01/23/2014	[no dates]		Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006
1096	Complaint, Dkt. 1, No. 09-cv-00199 (D.N.J.)	01/01/2009	Dkt. 1, No. 09-cv-00199 (D.N.J.)		Hearsay
1097	Answer and Counterclaims, Dkt. 11, No. 09-cv-00199 (D.N.J.)	03/06/2009	Dkt. 11, No. 09-cv-00199 (D.N.J.)		Hearsay
1098	Answer and Amended Counterclaims, Dkt. 16, No. 09-cv-00199 (D.N.J.)	04/01/2009	Dkt. 16, No. 09-cv-00199 (D.N.J.)		Hearsay
1099	Consent Order of Dismissal, Dkt. 65, No. 09-cv-00199 (D.N.J.)	06/13/2011	Dkt. 65, No. 09-cv-00199 (D.N.J.)		
1100	Civil Docket, No. 09-cv-00199 (D.N.J.)	12/24/2013	[no dates]		Hearsay; Relevance
1101	Complaint, Dkt. 1, No. 09-cv-05404 (D.N.J.)	10/21/2009	Dkt. 1, No. 09-cv-05404 (D.N.J.)		Hearsay
1102	Answer, Defenses and Counterclaims, Dkt. 12, No. 09-cv-05404 (D.N.J.)	12/24/2013	[no dates]		Hearsay
1103	Consent Judgment, Dkt. 74, No. 09-cv-05404 (D.N.J.)	01/26/2012	Dkt. 74, No. 09-cv-05404 (D.N.J.)		
1104	Civil Docket, No. 09-cv-05404 (D.N.J.)	12/24/2013	[no dates]		Hearsay; Relevance
1105	Complaint, Dkt. 1, No. 11-cv-04468 (D.N.J.)	08/02/2011	Dkt. 1, No. 11-cv-04468 (D.N.J.)		Hearsay
1106	Consent Judgment, Dkt. 23, No. 11-cv-04468 (D.N.J.)	04/17/2012	Dkt. 23, No. 11-cv-04468 (D.N.J.)		
1107	Civil Docket, No. 11-cv-04468 (D.N.J.)	12/24/2013	[no dates]		Hearsay; Relevance

Document #	Description	Date	Entered Date	Beg Doc	End Doc	Additional Notes	REvised/Objection
1108	Complaint, Dkt. 1, No. 12-cv-00506 (D.N.J.)	01/26/2012	Dkt. 1, No. 12-cv-00506 (D.N.J.)				Hearsay
1109	Consent Judgment, Dkt. 12, No. 12-cv-00506 (D.N.J.)	05/18/2012	Dkt. 12, No. 12-cv-00506 (D.N.J.)				
1110	Civil Docket, No. 12-cv-00506 (D.N.J.)	12/24/2013	[no bases]				Hearsay; Relevance
1111	First Amended Complaint, Dkt. 52, No. 12-cv-01378 (D.N.J.)	11/14/2012	Dkt. 52, No. 12-cv-01378 (D.N.J.)				Hearsay
1112	Answer, Separate Defenses and Counterclaims to First Amended Complaint, Dkt. 57, No. 12-cv-01378 (D.N.J.)	12/04/2012	Dkt. 57, No. 12-cv-01378 (D.N.J.)				Hearsay
1113	AstraZeneca's Brief in Support of its Motion to Amend the Complaint to Assert Infringement of U.S. Patent No. 5,948,789, Dkt. 105-6, No. 12-cv- 01378 (D.N.J.)	06/21/2013	Dkt. 105-6, No. 12-cv-01378 (D.N.J.)				Hearsay
1114	Civil Docket, No. 12-cv-01378 (D.N.J.)	09/20/2014	[no bases]				Hearsay; Relevance
1115	Complaint, Dkt. 1, No. 13-cv-01669 (D.N.J.)	03/19/2013	Dkt. 1, No. 13-cv-01669 (D.N.J.)				Hearsay
1116	Answer, Separate Defenses and Counterclaims, Dkt. 9, No. 13-cv- 01669 (D.N.J.)	06/03/2013	Dkt. 9, No. 13-cv-01669 (D.N.J.)				Hearsay
1117	Civil Docket, No. 13-cv-01669 (D.N.J.)	09/20/2014	[no bases]				Hearsay
1118	Complaint, Dkt. 1, No. 13-cv-04854 (D.N.J.)	08/12/2013	Dkt. 1, No. 13-cv-04854 (D.N.J.)				Hearsay
1119	Civil Docket, No. 13-cv-04854 (D.N.J.)	09/20/2014	[no bases]				Hearsay; Relevance
1120	Complaint, Dkt. 1, No. 13-cv-07298 (D.N.J.)	12/03/2013	Dkt. 1, No. 13-cv-07298 (D.N.J.)				Hearsay; Relevance
1121	Civil Docket Sheet, No. 13-cv-07298 (D.N.J.)	09/20/2014	[no bases]				Hearsay; Relevance
1122	Complaint, Dkt. 1, No. 13-cv-07299 (D.N.J.)	12/03/2013	Dkt. 1, No. 13-cv-07299 (D.N.J.)				Hearsay; Relevance
1123	Civil Docket Sheet, No. 13-cv-07299 (D.N.J.)	09/20/2014	[no bases]				Hearsay; Relevance
1124	Letter from AstraZeneca counsel to Ranbaxy	10/25/2005	RAN-ESM/0088194	RAN-ESM/0088197			Authenticity; Hearsay; Relevance
1125	Letter from Ranbaxy to AstraZeneca counsel	10/27/2005	NEX-RBX 3426749	NEX-RBX 3426750			Hearsay; Relevance
1126	Letter from AstraZeneca counsel to Ranbaxy	10/31/2005	NEX-RBX 3426808	NEX-RBX 3426809			Hearsay; Relevance
1127	Letter from Ranbaxy to AstraZeneca counsel	11/02/2005	NEX-RBX 3426752	NEX-RBX 3426753			Double Hearsay; Hearsay; Relevance
1128	Letter from Ranbaxy counsel to AstraZeneca counsel	11/04/2005	RAN-ESM/0088295	RAN-ESM/0088295			Authenticity; Hearsay; Relevance
1129	Letter from Ranbaxy counsel to AstraZeneca counsel	11/07/2005	RAN-ESM/0088293	RAN-ESM/0088294			Authenticity; Hearsay; Relevance
1130	Letter from Ranbaxy counsel to AstraZeneca counsel	11/11/2005	RAN-ESM/0088291	RAN-ESM/0088292			Authenticity; Hearsay; Unfairly Prejudicial; Relevance
1131	Letter from AstraZeneca counsel to IVAX	02/06/2006	Teva-ESO-032242	Teva-ESO-032244			Authenticity; Incomplete
1132	Letter from IVAX counsel to AstraZeneca counsel	02/13/2006	Teva-ESO-032240	Teva-ESO-032240			Authenticity; Incomplete

Ref#	Description	Date	Bef Doc#	End Doc#	Additional Dates	REVISED OBJECTION
1133	Letter from DRl counsel to AstraZeneca counsel, No. 05-cv-05535 (D.N.J.)	05/26/2010	AZ-NX-MDL-00000534	AZ-NX-MDL-00000535		Hearsay Cumulative; Double Hearsay; Hearsay; Unfairly Prejudicial; Not a proper summary under Rule 1006
1134	Rule 1006 Summary of Other AstraZeneca Litigation	02/08/2014	[no Bates]			
1138	Answer and Amended Counterclaims of Defendant Sandoz Inc., Dkt. 19, No. 09-cv-00159 (D.N.J.)	05/06/2009	[no Bates]			
1139	Sandoz Complaint Against Merck, Dkt. 23, No. 09-cv-00159 (D.N.J.)	05/12/2009	[no Bates]			Hearsay
1140	Sandoz' Memorandum in Opposition to Plaintiffs' - Counterclaim-Defendants' Motion to Stay the Case and Bifurcate Amended Counterclaims XI-XVI, Dkt. 28, No. 09-cv-00159 (D.N.J.)	06/01/2009	[no Bates]			Hearsay
1141	Defendants Mylan Inc. and Mylan Laboratories Limited's™ Amended Answer, Separate Defenses and Counterclaims to First Amended Complaint, Dkt. 78, No. 12-cv-01378 (D.N.J.)	02/25/2013	[no Bates]			Hearsay
1142	Defendants Wockhardt Limited and Wockhardt USA LLC's™ Answer, Affirmative Defenses and Counterclaims, Dkt. 8, No. 13-cv-04854 (D.N.J.)	11/20/2013	[no Bates]			Hearsay
1143	Letter from AstraZeneca counsel to DRl counsel, No. 05-cv-05535 (D.N.J.), with fax cover sheet	03/03/2010	DRLM/211124	DRU/MDL 211125		Hearsay Authenticity; Hearsay
1151	Astra HÄssle Clinical Study Report No. SH-QBE-0001	01/16/1997	NEX-RBX 0002670	NEX-RBX 0002921		Relevance Hearsay
1152	Astra Merck Protocol No. 172, Draft No. SH-QBE-0002	04/07/1997	NEX-RBX 2493368	NEX-RBX 2893416		Incomplete
1153	Astra HÄssle Clinical Study Report No. SH-QBE-0008	04/13/1997	NEX-RBX 2429078	NEX-RBX 2429111		
1154	Astra HÄssle Clinical Study Report No. SH-QBE-0008	04/14/1997	AZ-NX-MDL-00669509	AZ-NX-MDL-00669538		
1155	Astra Pharmaceuticals, L.P. Data Analysis Plan for H198/18 Protocol 172, Draft Tables	06/11/1998	NEX-RBX 2351679	NEX-RBX 2351727		Authenticity; Hearsay; Incomplete; Relevance
1156	Astra Pharmaceuticals, L.P. Data Analysis Plan for H199/18 Protocol 172, Draft	06/16/1998	NEX-RBX 2351676	NEX-RBX 2351678		Authenticity; Hearsay; Incomplete
1157	Astra Pharmaceuticals, L.P. Data Analysis Plan for H199/18 Protocol 172, Draft	07/07/1998	NEX-RBX 2351728	NEX-RBX 2351735		Authenticity; Hearsay; Incomplete
1158	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Draft	12/14/1998	NEX-RBX 2887521	NEX-RBX 2887628		Hearsay
1159	Notes for Nelimus Presentation, Lisa Schoenberg, presenter	01/05/1999	AZ-NX-MDL-01232432	AZ-NX-MDL-01232436		Hearsay; Relevance
1160	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Draft	01/27/1999	NEX-RBX 2089937	NEX-RBX 2090044		Incomplete
1161	Astra HÄssle minutes, January 25, 1999 Esomeprazole (H199/18) European Marketing Strategy Meeting	02/17/1999	AZ-NX-MDL-00651706	AZ-NX-MDL-00651715		Hearsay
1162	Astra HÄssle Clinical Study Report No. SH-QBE-0021	04/27/1999	AZ-NX-MDL-00680129	AZ-NX-MDL-00680241		

Plaintiff	Description	Date	Evidence	Additional Notes	REvised Objection
1163	Astra-Hässle Clinical Study Report No. SH-QBE-0009	05/12/1999	AZ-NX-MDL-00679705	AZ-NX-MDL-00579815	
1164	Astra-Hässle Clinical Study Report No. SH-QBE-0011	05/12/1999	AZ-NX-MDL-00679982	AZ-NX-MDL-00580118	
1165	Astra Pharmaceuticals, L.P. Clinical Study Report 172, without appendices	05/20/1999	NEX-RBX 0138618	NEX-RBX 0139032	
1166	Astra Pharmaceuticals, L.P. Clinical Study Report 172, List of Appendices	05/20/1999	NEX-RBX 0139049	NEX-RBX 0139057	Incomplete; Relevance; Unfairly Prejudicial
1167	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Appendix 16.1, Astra Merck Protocol No. 172,	05/20/1999	NEX-RBX 0139058	NEX-RBX 0139127	
1168	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Appendix 16.1, Amendment No. 1 dated August 29, 1997	05/20/1999	NEX-RBX 0139977	NEX-RBX 0139986	Incomplete; Relevance
1169	Astra-Hässle Clinical Study Report No. SH-QBE-0050	12/15/1999	NEX-RBX 0064888	NEX-RBX 0065177	Incomplete
1170	Astra-Hässle Clinical Study Report No. SH-QBE-0066	02/10/2000	NEX-RBX 0116132	NEX-RBX 0116469	NEX-RBX 0065760 - 0055341
1171	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/08/2001	AZ-NX-MDL-01240264.wmv	[native file]	Relevance
1172	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/08/2001	AZ-NX-MDL-01240266.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1173	Video (VTS_01_1.wmv) from National Nexium Sales Meeting, January 9, 2001	01/09/2001	AZ-NX-MDL-01240379.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1174	Screen shot from video (VTS_01_1.wmv) from National Nexium Sales Meeting, January 9, 2001, at 6:25"	01/09/2001	[no Bates]		Authenticity; Hearsay; Relevance; Unfairly Prejudicial
1175	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240267.wmv	[native file]	Authenticity; Hearsay; Incomplete
1176	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240268.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1177	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240269.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1178	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240270.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1179	Video clip (Oclip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/10/2001	AZ-NX-MDL-01240272.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1180	Video clip (1clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/10/2001	AZ-NX-MDL-01240274.wmv	[native file]	Hearsay; Relevance; Unfairly Prejudicial
1181	Market Measures Interactive Fastape Plus Study #42186, PPS: Nexium Wave 1, prepared for AstraZeneca	05/15/2001	AZ-NX-MDL-01235572	AZ-NX-MDL-01235982	Double Hearsay; Hearsay; Relevance

Document Number	Description	Date	Relevant Date	Case Name/Doc#	Additional Dates	Revised Objectection
1182	Market Measures Interactive Fastape Plus Study #42287, Proton Pump Inhibitors: Nexium Wave II, prepared for AstraZeneca	08/03/2001	AZ-NX-MDL-01235983	AZ-NX-MDL-01235604		Double Hearsay; Relevance
1183	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 11, prepared for AstraZeneca	11/01/2001	AZ-NX-MDL-01237087	AZ-NX-MDL-01237160		Double Hearsay; Relevance
1184	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 12, prepared for AstraZeneca	11/30/2001	AZ-NX-MDL-01237161	AZ-NX-MDL-01237228		Double Hearsay; Relevance
1185	Market Measures Interactive Fastape Plus Study #42413, Nexium Refresh, prepared for AstraZeneca	12/14/2001	AZ-NX-MDL-01235605	AZ-NX-MDL-01237085		Double Hearsay; Relevance
1186	AstraZeneca document, Selling NEXUM in a Highly Penetrated Managed Care Environment, Orange County DSMs	04/01/2002	AZ-NX-MDL-01235551	AZ-NX-MDL-01235558		Double Hearsay; Relevance
1187	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 17, prepared for AstraZeneca	05/28/2002	AZ-NX-MDL-01237229	AZ-NX-MDL-01237302		Hearsay; Unfair Prejudicial
1188	Presentation by Dr. Grahek. Preventing Recurrent Esophageal Erosions: The Benefits of Maintenance Therapy.	03/01/2003	AZ-NX-MDL-01233004	AZ-NX-MDL-01233040		Double Hearsay; Relevance
1189	Presentation by Dr. Grahek. Severity of GERD Symptoms and Disease: The Complex Relationship Between Symptoms and Erosions.	03/01/2003	AZ-NX-MDL-01233041	AZ-NX-MDL-01233077		Hearsay; Relevance
1190	Astra presentation. NEXUM® Top 10.	10/01/2003	AZ-NX-MDL-01232503	AZ-NX-MDL-01232515		Hearsay; Relevance
1191	Statement by D. Levine, M.D., representing AstraZeneca, to the Oregon Health Resources Commission	04/16/2004	AZ-NX-MDL-01232622	AZ-NX-MDL-01232629		Hearsay; Relevance
1192	E-mail from C. Watson to K. Fagge-Stephenson with attached TAK-390 MR / Dexlansoprazole slides	03/12/2008	NEX-RBX 3481140	NEX-RBX 3481185		Hearsay; Relevance
1193	AstraZeneca Formulary Submission Dossier, NEXUM® (esomeprazole magnesium) Delayed-Release Capsules	undated	AZ-NX-MDL-01231555	AZ-NX-MDL-01231974		Hearsay
1194	AstraZeneca Core Visual Aid	undated	AZ-NX-MDL-01232336	AZ-NX-MDL-01232361		Double Hearsay; Relevance
1195	Reprint of Kahlillas P, Falk GW, Johnson DA, et al. Allinent Pharmacology. 2003;96(3):655-65.	undated	AZ-NX-MDL-01232369	AZ-NX-MDL-01232380		Hearsay; Relevance
1196	Reprint of Richter JE, Kahnlas PJ, Johnson J, et al. Am J Gastroenterol. 2003;96(3):655-65.	undated	AZ-NX-MDL-01232381	AZ-NX-MDL-01232392		Hearsay
1197	Astra presentation. Managing GERD Symptoms in the Geriatric Patient, version 25.	undated	AZ-NX-MDL-01232393	AZ-NX-MDL-01232423		Hearsay; Relevance
1198	Astra presentation. PPI Treatment of GERD.	undated	AZ-NX-MDL-01232630	AZ-NX-MDL-01232705		Hearsay
1199	Astra presentation. CVA Workshop.	undated	AZ-NX-MDL-01232987	AZ-NX-MDL-01233003		Hearsay; Relevance
1200	AstraZeneca Annual Business Review presentation by C. Fitzsimons, Nexium® The Leading PPI by value in 2005 and beyond	undated	AZ-NX-MDL-01237609	AZ-NX-MDL-01237621		Double Hearsay; Relevance

Exhibit	Description	Date	BerDoc	BerDoc	Additional Bates	REVISED OBJECTION
1201	Bell NJ, Burget D, Howden CW, et al. Digestion. 1992; 15(Suppl 1):59-67.	01/01/1992	KESSELHEIMNEXMA000199	07	KESSELHEIMNEXMA0002	Hearsay
1202	Bate CM, Booth N, Hepworth-Jones B, et al. Aliment Pharmacol Ther. 1993;7:501-7.	06/01/1993	[no dates]			Hearsay
1204	Chang M, Tybring G, Dahl M-L, et al. Br J Clin Pharmacol. 1995;39(5):117-8.	01/01/1995	[no dates]			Hearsay
1206	Gan KH, Geus WP, Lamers CB, Heijerman HG. Dig Dis Sci. 1997;42(1):2304-9.	11/01/1997	[no dates]			Hearsay
1207	Andersson T, Holmberg J, Rohas K, Wanat A. Br J Clin Pharmacol. 1998;45:369-75.	01/01/1998	[no dates]			Hearsay
1208	Adams KF. Amer Heart J. 1998;136:753-8.	11/01/1998	KESSELHEIMNEXMA000296	01	KESSELHEIMNEXMA0003	Hearsay
1210	Ferguson RP, Rhim E, Belzaire W, et al. Am J Med. 1999 Aug;107:149-52.	08/01/1999	ABRAMSONNEXMA000058	61	ABRAMSONNEXMA0000	Hearsay
1211	Kahlhas PJ, Fall GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14(10):1249-56.	01/01/2000	ABRAMSONNEXMA00261	70	ABRAMSONNEXMA0002	Hearsay
1212	Lind T, Rydbergl, KyleBäck A, et al. Aliment Pharmacol Ther. 2000;14(7):861-7.	01/01/2000	KESSELHEIMNEXMA00162	68	KESSELHEIMNEXMA0001	Hearsay
1216	Thitiphuree S, Valley NJ. Int J Clin Pract. 2000;54(8):537-41.	10/01/2000	KESSELHEIMNEXMA000004	08	KESSELHEIMNEXMA0000	Hearsay
1217	Veldeurzen van Zanten S, Lauritsen K, Delchier JC, et al. Aliment Pharmacol Ther. 2000;14(12):1605-11.	12/01/2000	KESSELHEIMNEXMA000343	49	KESSELHEIMNEXMA0003	Hearsay
1218	Andersson T, Råthas K, Hassan-Alin M, et al. Gastroenterology. 2000;118( Pt 2):A1210.	12/31/2000	[no dates]			Hearsay
1219	Andersson T, Hassan-Alin M, Hasselgren G, et al. Clin Pharmacol. 2001;40(6):11-26.	01/01/2001	KESSELHEIMNEXMA000009	24	KESSELHEIMNEXMA0000	Hearsay
1220	Hasselgren G, Hassan-Alin M, Andersson T, et al. Clin Pharmacol. 2001;40(2):145-50.	01/01/2001	[no dates]			Hearsay
1222	Richter JE, Kahlhas PJ, Johnson J, et al. Am J Gastroenterol. 2001 Mar;96(3):556-65.	03/01/2001	KESSELHEIMNEXMA00218	27	KESSELHEIMNEXMA0002	Hearsay
1226	Tulassy Z, Kryszewski A, Dite P, et al. Eur J Gastroenterol Hepatol. 2001;13(12):1457-65.	12/01/2001	KESSELHEIMNEXMA000350	58	KESSELHEIMNEXMA0003	Hearsay
1227	National Survey of Physicians Part II: Doctors and Prescription Drugs. The Kaiser Family Foundation, March 2002. <a href="http://www.kff.org/nrdnugs/loader.cfm?c=135656&amp;PagedID=135656">http://www.kff.org/nrdnugs/loader.cfm?c=135656&amp;PagedID=135656</a> . Accessed on July 25, 2007.	03/01/2002	ABRAMSONNEXMA00062	70	ABRAMSONNEXMA0000	Hearsay / Relevance
1228	Råthas K, Hasselgren G, Hedenskamp H. Dig Dis Sci. 2002;47(5):1944-8.	05/01/2002	KESSELHEIMNEXMA000169	73	KESSELHEIMNEXMA0001	Hearsay
1229	Steinbrook R. N Engl J Med. 2005 May 26;352(21):2160-2.	05/26/2002	ABRAMSONNEXMA00091	93	ABRAMSONNEXMA0000	Hearsay

SPINE#	Description	Date	Bridgeman	Additional Refs.	REvised Objection
1132	Hensley S. Wall Street Journal. 2002 Dec 4; Section A1.	12/04/2002	ABRAMSONNEXMA00037	ABRAMSONNEXMA0002	Hearsay; Relevance
1235	Miner P., Katz PO, Chen Y, Sostek M. Am J Gastroenterol. 2003;188(12):2616-20. Amendment. Am J Gastroenterol. 2006;101(2):404-5.	01/01/2003	KESSELHEIMNEXMA00074	KESSELHEIMNEXMA0001 81	
1237	Moynihan R. Br Med J. 2003 May 31;326:1189-92.	05/31/2003	ABRAMSONNEXMA00054	ABRAMSONNEXMA0000	Hearsay
1240	Miehlke S, Schneider-Brachter W, Babststein E, et al. Aliment Pharmacol Ther. 2003;18(8):799-804.	08/01/2003	[no bates]	57	Hearsay; Relevance
1241	Vakil N, Fennerty MB. Aliment Pharmacol Ther. 2003;18:559-68.	08/01/2003	[no bates]		Hearsay
1245	Armstrong D, Talley NJ, Lauritsen K, et al. Aliment Pharmacol Ther. 2004;24(4):413-21.	01/01/2004	ABRAMSONNEXMA000292	ABRAMSONNEXMA0003	Hearsay
1246	Huh KC, Lee IH, Yang YW, et al. Gastroenterology. 2004;126:A190-A191.	01/01/2004	[no bates]	60	Hearsay
1248	Anagnostopoulos GK, Tsaiakos S, Margantinis G, et al. J Clin Gastroenterol. 2004;3(6):503-6.	07/01/2004	KESSELHEIMNEXMA000359	KESSELHEIMNEXMA0003 62	Hearsay
1249	Hassan-Alin M, Andersson T, Niazi M, RA Shiss K. Eur J Clin Pharmacol. 2005;60(11):779-84.	09/16/2004	KESSELHEIMNEXMA00025	KESSELHEIMNEXMA0000	Hearsay
1250	Elliott S, Yves N. New York Times. 2004 Oct 12; Section C-1.	10/12/2004	[no bates]	30	Hearsay
1253	Sierra F, Torres D, Martinez O, Gorslick J. Gastroenterology. 2005;128 (Suppl 2):A51.	01/01/2005	KESSELHEIMNEXMA000228	KESSELHEIMNEXMA0002	Double hearsay; Hearsay; Relevance; Unfairly Prejudicial
1254	Sheu B-S, Kao A-W, Cheng H-C, et al. Aliment Pharmacol Ther. 2005;21(3):283-8.	02/01/2005	[no bates]	28	Hearsay
1255	Berenson A. New York Times. 2005 Mar 3.	03/03/2005	KESSELHEIMNEXMA000001	KESSELHEIMNEXMA0000	Hearsay; Relevance
1258	Chen C-Y, Lu C-, Luo J-C, et al. World J Gastroenterol. 2005;11(20):3112-7.	05/28/2005	KESSELHEIMNEXMA000229	KESSELHEIMNEXMA0002 34	Hearsay
1261	Lighthill CJ, Schmitt C, Hwang C, Hamelin B. Dig Dis Sci. 2006;51(5):882-7.	01/01/2006	KESSELHEIMNEXMA000242	KESSELHEIMNEXMA0002 48	Hearsay
1265	Schmitt C, Lighthill CJ, Hwang C, Hamelin B. Dig Dis Sci. 2006;51(5):884-50.	04/01/2006	KESSELHEIMNEXMA000235	KESSELHEIMNEXMA0002 41	Hearsay
1267	Kesselheim AS, Fischer MA, Avorn J. Health Affairs. 2006;25(6):1095-102.	07/01/2006	KESSELHEIMNEXMA000191	KESSELHEIMNEXMA0001 98	Hearsay; Relevance
1270	Katz PO, Ginsberg GG, Hoyle PE, et al. Aliment Pharmacol Ther. 2007;25:617-28.	01/01/2007	[no bates]		Hearsay
1271	Subel I, M, Cardona HI, Bachelder E, et al. Dig Dis Sci. 2007;52(6):1505-12.	04/01/2007	KESSELHEIMNEXMA000363	KESSELHEIMNEXMA0003 70	Hearsay

PLATE	Description	Date	Def Doc	Def Doc	Additional Date	REvised Objection
1272	Arnold M. Med Market Media. 2007 Aug 9 2007. <a href="http://www.mmm-online.com/FDA-eyes-Nexium-Philosec-for-heart-risks-with-ampquately-communicationquot/article/24925/">http://www.mmm-online.com/FDA-eyes-Nexium-Philosec-for-heart-risks-with-ampquately-communicationquot/article/24925/</a> . Accessed on September 5, 2011.	08/09/2007	ABRAMSONNEXMA000035	ABRAMSONNEXMA000035	35	
1274	Abrhanyan L, Johnson SR, Bevenc J, et al. Rheumatology (Oxford). 2005;47(5):640-5.	02/02/2008	[no Bates]			Hearsay; Relevance
1276	Zheng RN, Wong J. Gastroenterol. 2009 Feb;28(18):990-5.	02/28/2009	KESSELEIMNEXMA00249	KESSELEIMNEXMA00249	54	
1278	Katz MH. Arch Intern Med. 2010 May 10;170(10):747-8.	05/10/2010	[no Bates]			Hearsay
1284	Doebler SA. Comparative Claims: Learning from FDA Warning and Untitled Letters. Regulatory Focus Online. 2012 Nov 9. <a href="http://www.raps.org/focus-online/news/news-article-view/article/2522/comparative-claims.aspx">http://www.raps.org/focus-online/news/news-article-view/article/2522/comparative-claims.aspx</a> .	11/09/2012	[no Bates]			Hearsay
1289	Vacek D. Top 200 Drugs of 2002. Pharmacy Times. <a href="http://www.pharmacytimes.com/article.cfm?ID=338">http://www.pharmacytimes.com/article.cfm?ID=338</a> . Accessed on August 14, 2007.	undated	ABRAMSONNEXMA000016	ABRAMSONNEXMA000000	18	Authenticity; Hearsay
1290	FDA Guidance for Industry, Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Rockville (MD): FDA; 1998 May.	05/01/1998	[no Bates]			Hearsay; Relevance
1293	NDA 21-153. Gallo-Torres HE. Medical Officer's Review. HE. Statistical Review and Evaluation (Clinical).	09/21/2000	NEX-RBX 0585755	NEX-RBX 0585930		
1294	NDA 21-153. Tsong Y, Gallo-Torres HE. Statistical Review and Evaluation (Clinical).	10/03/2000	A2-NX-MDL-01238069	A2-NX-MDL-01238106		Hearsay; Relevance
1295	NDA 21-153. Fax from FDA to AstraZeneca with attached approvable labeling for Nexium.	10/04/2000	A2-NX-MDL-01233765	A2-NX-MDL-01233814		Authenticity; Hearsay; Misleading; Relevance
1296	NDA 21-153. Other: Background Information for Labeling Meeting.	10/27/2000	A2-NX-MDL-01234147	A2-NX-MDL-01234153		Hearsay; Relevance; Unfairly Prejudicial
1297	NDA 21-154. Hundleby SG. Pharmacology/Toxicology Review and Evaluation.	10/31/2000	A2-NX-MDL-01238064	A2-NX-MDL-01238063		Hearsay; Relevance; Unfairly Prejudicial
1298	NDA 21-153. Fax from FDA to AstraZeneca with attached revised clinical section of Nexium labeling.	12/07/2000	A2-NX-MDL-01234457	A2-NX-MDL-01234471		Authenticity; Hearsay; Misleading; Relevance
1299	NDA 21-154. Meyer JM, Higgins K. Clinical and Statistical Review.	12/15/2000	RAN-ESM0076804	RAN-ESM0076843	RAN-ESM0076874 - RAN-ESM0076880; RAN-ESM0076873; RAN-ESM0076881 - RAN-ESM0076996	Hearsay; Relevance; Unfairly Prejudicial; Incomplete; Authenticity; Hearsay; Relevance
1300	Approvable Letters for NDA 21-153 and NDA 21-154. <a href="http://www.accessdata.fda.gov/drugatfda_docs/nda/2002/21154_Nexiu_m_Approval.pdf">http://www.accessdata.fda.gov/drugatfda_docs/nda/2002/21154_Nexiu_m_Approval.pdf</a>	12/15/2000	[no Bates]			Authenticity; Hearsay

Index	Description	Date	BigDoc	EndDoc	Additional Status	REVISED/OBJECTION
1301	NDA 21-153. General Correspondence: Response to FDA Labelling Revisions dated February 1, 2001.	02/05/2001	AZ-NX-MDL-01234841	AZ-NX-MDL-01234878		Hearsay; Relevance; Unfairly Prejudicial
1302	NDA 21-153. General Correspondence: Revised Draft Nexium label.	02/08/2001	AZ-NX-MDL-01234879	AZ-NX-MDL-01234911		Hearsay; Relevance; Unfairly Prejudicial
1305	NDA 21-153. Approved label for NEXUM. <a href="http://www.accessdata.fda.gov/drugatfda_docs/label/2001/21133lbl.pdf">http://www.accessdata.fda.gov/drugatfda_docs/label/2001/21133lbl.pdf</a>	02/20/2001	[no Bates]			Hearsay; Relevance; Unfairly Prejudicial
1306	NDA 21-153. Response to FDA's February 20, 2001 Request for Introductory Promotional Materials.	03/13/2001	NEX-RBX 0439902	NEX-RBX 0439132		Authenticity; Hearsay; Relevance
1307	NDA 21-153. General Correspondence: February 6, 2001 Sponsor Meeting Minutes [Labeling Discussions]	03/15/2001	AZ-NX-MDL-01235069	AZ-NX-MDL-01235134		Hearsay; Relevance; Unfairly Prejudicial
1308	NDA 21-153. FDA response to proposed promotional materials.	03/16/2001	AZ-NX-MDL-01232362	AZ-NX-MDL-01232368		Hearsay; Relevance
1309	FDA. Guidance for Industry, E 10 Choice of Control Group and Related Issues in Clinical Trials. Rockville (MD): FDA; 2001 May.	05/01/2001	[no Bates]			Hearsay; Relevance
1311	NDA 20-536. Approved label for ATACANO.	09/15/2002	[no Bates]			Authenticity; Hearsay
			<a href="http://www.accessdata.fda.gov/drugatfda_docs/label/2002/20838s015lb1.pdf">http://www.accessdata.fda.gov/drugatfda_docs/label/2002/20838s015lb1.pdf</a>			
1312	NDA 20-584. Letter from FDA DDMAC to Boehringer Ingelheim	03/22/2005	[no Bates]			Authenticity; Hearsay; Relevance
1314	Pharmaceuticals, Inc. FDA. Guidance For Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products -Content and Format. Rockville (MD): FDA; 2006 Jan.	01/01/2006	[no Bates]			Authenticity; Hearsay; Relevance
1315	U.S. Government Accountability Office. Prescription Drugs, Improvements Needed In FDA's Oversight of Direct-to-Consumer Advertising. GAO-07-054.	11/16/2006	[no Bates]			Authenticity; Hearsay; Relevance
1317	Washington (DC); U.S. Government Accountability Office; 2006 Nov. Temple R (Deputy Center Director for Clinical Science, CDER, FDA). Comparative Effectiveness Research. Presentation at FDA/DIA Statistics Forum. 2010 Apr 21.	04/21/2010	[no Bates]			Authenticity; Hearsay; Relevance

Case No.	Description	Date:	Burdened	Additional Burdened	Endorse	Reviewed
1318	Aiken KJ (DDMAC, OMP, CDER). An Introduction to the Regulation of Prescription Drug Promotion: The Role of FDA. Presentation at: Medical Library Association Annual Meeting. <a href="http://www.fda.gov/downloads/CenterforMedicineandFDA/CentersOffices/CDER/UCM266150.pdf">http://www.fda.gov/downloads/CenterforMedicineandFDA/CentersOffices/CDER/UCM266150.pdf</a> .	05/24/2010	[no bates]			Authenticity; Hearsay; Relevance
1319	Klester M (Associate Director of Operations, DDMAC, DDMAC Submissions. Presentation.	<a href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ForSubmissionRequirements/ElectronicSubmissions/UCM246563.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ForSubmissionRequirements/ElectronicSubmissions/UCM246563.pdf</a>	02/09/2011	[no bates]		Authenticity; Hearsay; Relevance
1320	Update to FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, March 25, 2011. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, May 25, 2010.	<a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm</a> .	03/23/2011	[no bates]		Authenticity; Hearsay; Relevance
1321	NDA 20-541, Approved label for ARIMIDEX, reference ID: 2920600.	<a href="http://www.accessdata.fda.gov/drugatfdocs/label/2011/020541s0261.pdf">http://www.accessdata.fda.gov/drugatfdocs/label/2011/020541s0261.pdf</a>	04/18/2011	[no bates]		Authenticity; Hearsay; Relevance; Unfairly Prejudicial
1322	Glossary of Terms. Drugs@FDA. U.S. Food and Drug Administration website. Last updated on February 2, 2012.	<a href="http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm">http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm</a> .	02/02/2012	[no bates]		Authenticity; Hearsay; Relevance
1324	Abrams T (Director, Office of Prescription Drug Promotion). OOPP Update on Oversight of Prescription Drug Promotion. Presentation.	<a href="http://www.fda.gov/downloads/CenterforMedicineandFDA/CentersOffices/OfficeofMedicalProductsandTobacco/cder/ucm330855.pdf">http://www.fda.gov/downloads/CenterforMedicineandFDA/CentersOffices/OfficeofMedicalProductsandTobacco/cder/ucm330855.pdf</a>	10/01/2012	[no bates]		Authenticity; Hearsay; Relevance

Exhibit	Description	Date	Becket	Opposition	Additional Dates	Revised Conclusion
1326	Nexium, Drug Details. Drugs@FDA. U.S. Food and Drug Administration website. <a 022307s008lbl.pdf"="" 2013="" drugatfda_docs="" href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?useaction=SearchSet_Current_Drug&amp;ApplicationID=11534&amp;DrugName=NEXIUM&amp;ActiveIngredient=ESOMIEPERAZOLE%20MA&amp;NDAUMR&amp;SponsororApplicant=ASTRAZENECA&amp;ProductMktStatus=1&amp;go=SearchDrugDetails. Accessed on August 19, 2013.&lt;/a&gt;&lt;/td&gt;&lt;td&gt;08/19/2013&lt;/td&gt;&lt;td&gt;[no dates]&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td&gt;1327&lt;/td&gt;&lt;td&gt;NDA 22-507, Approved label for EFFIENT, reference ID: 3391282. &lt;a href=" http:="" label="" www.accessdata.fda.gov="">http://www.accessdata.fda.gov/drugatfda_docs/label/2013/022307s008lbl.pdf</a>	10/16/2013	[no dates]			Authenticity; Hearsay; Relevance
1328	21 CFR Å 201.56	undated	[no dates]			Relevance
1329	21 CFR Å 201.57	undated	[no dates]			Relevance
1330	21 CFR Å 202.1	undated	[no dates]			Relevance
1331	21 CFR Å 314	undated	[no dates]			Hearsay; incomplete
1332	21 U.S.C. Å 355	undated	[no dates]			Hearsay; incomplete
1333	40 Fed. Reg. 58,794	12/18/1975	[no dates]			Relevance
1334	40 Fed. Reg. 74,817	12/18/1973	[no dates]			Relevance
1335	60 Fed. Reg. 52,196	10/05/1995	[no dates]			Relevance
1336	71 Fed. Reg. 3,322	01/24/2006	[no dates]			Relevance
1337	Toy A (Arnold & Porter) FDA Regulation of Advertising and Promotion. Presentation at Regulatory Affairs Professional Society: Regulatory Affairs Certification (RAC) Study Group. <a href="http://www.arnoldporter.com/resources/documents/RAP%20-%20FDA%20Regulation%20of%20Advertising%20and%20Promotion.pdf">http://www.arnoldporter.com/resources/documents/RAP%20-%20FDA%20Regulation%20of%20Advertising%20and%20Promotion.pdf</a>	07/14/2013	[no dates]			
1338	Screenshot from <a href="http://www.everythingbutanchoovies.com/everythingbutanchoovies/sample_launch/NEX/index.html">www.everythingbutanchoovies.com/everythingbutanchoovies/sample_launch/NEX/index.html</a> . Accessed on August 8, 2013.	08/08/2013	[no dates]			Authenticity; Hearsay; Relevance
1339	Letter from FDA to National Association of Boards of Pharmacy. Therapeutic Equivalence of Generic Drugs. <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approvals/AbbreviatedNewDrugApplications/NDAGenerics/ucm073224.htm">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approvals/AbbreviatedNewDrugApplications/NDAGenerics/ucm073224.htm</a>	04/16/1997	[no dates]			
1340	Astra Pharmaceuticals memorandum from D'Amico to Everett EF Working Group	01/27/1999	NEX-RBX 2885503	NEX-RBX 2885503		Authenticity; Double Hearsay
1341	Appendix Table 1 to Declaration of Aaron S. Kesselheim	08/23/2013	[no dates]			Hearsay; incomplete; Relevance
1342	Appendix Table 2 to Declaration of Aaron S. Kesselheim	08/23/2013	[no dates]			Hearsay

SPLK	Description	Date	B6D6	B6D6	Additional Boxes	REVISED OBJECTION
1343	Appendix Table I to Declaration of Aaron S. Kesselheim	08/23/2013	[no dates]			Authenticity; Double Hearsay; Hearsay; Relevance
1344	Appendix Table I to Rebuttal Declaration of Aaron S. Kesselheim	10/25/2013	[no dates]			Authenticity; Double Hearsay; Hearsay; Relevance
1345	Chart from Declaration of John Abramson, page 21	08/23/2013	[no dates]			Authenticity; Foundation; Hearsay; Relevance
1346	Table from Declaration of Aaron S. Kesselheim, page 6	08/23/2013	[no dates]			Authenticity; Hearsay; Relevance
1347	Collage prepared by David Kessler;	11/18/2013	[no dates]			Authenticity; Hearsay
1348	Inter-Patient Variability in Equal 40 mg Doses (table from page 31 of Declaration of John Abramson, MD dated August 23, 2013)	08/23/2013	[no dates]			Authenticity; Hearsay
1376	ANDA No. 77-830. Submission letter, Table of Contents, Section I, Signed Application Form, Section II, Basis for ANDA Submission.	08/04/2005	RAN-ESM0002529	RAN-ESM0002549		Expert Report; Foundation; Hearsay
1377	ANDA No. 77-830. Section III, Patent Certification and Exclusivity Statement.	08/04/2005	RAN-ESM0002550	RAN-ESM0002557		Incomplete; Relevance
1378	ANDA No. 77-830. Section IV, Comparison between the Generic Drug and Reference Listed Drug.	08/04/2005	RAN-ESM0002558	RAN-ESM0002605		Incomplete; Relevance
1379	ANDA No. 77-830. Section VII, Components and Compositions Statements.	08/04/2005	RAN-ESM0018578	RAN-ESM0018587		Incomplete; Relevance
1380	ANDA No. 77-830. Section VIII.1, Raw Materials, Active Ingredient(s).	08/04/2005	RAN-ESM0018588	RAN-ESM0018617		Incomplete; Relevance
1381	ANDA No. 77-830. Section IX, Description of Manufacturing Facility.	08/04/2005	RAN-ESM0018713	RAN-ESM0018720		Incomplete; Relevance
1382	ANDA No. 77-830. Section XI, Manufacturing and Processing Instructions.	08/04/2005	RAN-ESM0018723	RAN-ESM0018846		Incomplete; Relevance
1383	ANDA No. 77-830. Section XV.2.c, Test Specifications and Data.	08/04/2005	RAN-ESM0019241	RAN-ESM0019671 - RAN-ESM0019681		Incomplete; Relevance
1384	Letter from FDA to Ranbaxy	10/05/2005	RAN-ESM005612	RAN-ESM005615		Relevance
1385	ANDA No. 77-830. Amendment.	07/13/2006	RAN-ESM0089042	RAN-ESM0089217		Relevance
1387	ANDA No. 77-830. Amendment.	08/17/2007	RAN-ESM0081260	RAN-ESM0081743		Relevance
1388	Letter from FDA to Ranbaxy	11/19/2007	RAN-ESM 06125945	RAN-ESM 0625947		Relevance
1390	ANDA No. 77-830. Amendment and Request for Tentative Approval.	12/21/2007	RAN-ESM 0625948	RAN-ESM 0625948		Relevance
1391	Ranbaxy document. FDA Telephone Contact.	12/21/2007	RAN-ESM 0718953	RAN-ESM 0718953		Authenticity; Double Hearsay; Hearsay; Relevance
1392	E-mail from C. Brown to multiple recipients with attached letter from FDA to Ranbaxy	02/05/2008	RAN-ESM0173659	RAN-ESM0173665		Relevance
1393	ANDA No. 77-830. Amendment.	08/14/2008	RAN-ESM 0626134	RAN-ESM 0626147		Relevance
1394	Ranbaxy document. FDA Telephone Contact.	08/26/2008	RAN-ESM 0626149	RAN-ESM 0626150		Relevance
1395	ANDA No. 77-830. Amendment.	10/17/2008	RAN-ESM 0626178	RAN-ESM 0626180		Relevance
1396	ANDA No. 77-830. Amendment to Tentatively Approved ANDA. Form FDA 356h and cover letter.	11/15/2013	RAN-ESM 0774207	RAN-ESM 0774214		Authenticity; Hearsay; Relevance
1397	ANDA No. 77-830. Amendment.	11/15/2013	RAN-ESM 0774204	RAN-ESM 0793445		Missing Image/ Relevance
1401	DME No. 18359, Volume 1 of 3.	08/03/2005	RAN-ESM0001639	RAN-ESM0001664		Relevance
1402	DME No. 18558, Module 3.2.5.2. Manufacture.	08/03/2005	RAN-ESM0001655	RAN-ESM0001668		Incomplete; Relevance

RECEIVED	Description	Date	Entered By/Doc#	Entered Doc#	Additional Notes	REVIEWED/REJECTION
1404	DMF No. 18559, Module 2.2.5.A. Control of Drug Substance.	08/03/2005	RAN-ESM0001969	RAN-ESM0001979		Incomplete; Relevance
1405	DMF No. 18559, Module 2.2.5. Annexure-3, Certificates of Analysis.	08/03/2005	RAN-ESM002234	RAN-ESM002243		Incomplete; Relevance
1406	DMF No. 18559, Module 2.2.5. Reference Standards and Annexure-1, Spectroscopic Data of Working Standard of Active Substance.	08/03/2005	RAN-ESM002248	RAN-ESM002260		Incomplete; Relevance
1407	DMF No. 18559, Amendment.	06/29/2006	RAN-ESM0089259	RAN-ESM0089456		Incomplete; Relevance
1408	DMF No. 18559, Amendment. Submission letter, amendment (without annexures), and list of annexures.	08/17/2007	RAN-ESM0089457	RAN-ESM0089476		Incomplete; Relevance
1409	DMF No. 18559, Amendment. Annexure-VII, Specifications and Analytical Methods of Intermediates.	08/17/2007	RAN-ESM008926	RAN-ESM0089863		Incomplete; Relevance
1410	DMF No. 18559, Amendment. Annexure-XI, Certificates of Analysis.	08/17/2007	RAN-ESM00893979	RAN-ESM008988		Incomplete; Relevance
1411	DMF No. 18559, Amendment. Annexure-XII, Stability Data.	08/17/2007	RAN-ESM0089989	RAN-ESM0089995		Incomplete; Relevance
1412	ANDA No. 78-003, Submission letter: Table of Contents, Section I, Standard Application Form, Section II, Basis for ANDA Submission.	11/23/2005	Teva-ESO-000076	Teva-ESO-000106		Incomplete; Relevance
1413	ANDA No. 78-003, Section III, Patent Certification and Exclusivity Statement.	11/23/2005	Teva-ESO-000107	Teva-ESO-000112		Authenticity
1414	ANDA No. 78-003, Section IV, Comparison Between Generic Drug and Reference Listed Drug.	11/23/2005	Teva-ESO-000113	Teva-ESO-000119		Authenticity
1415	ANDA No. 78-003, Section V, Labeling.	11/23/2005	Teva-ESO-000120	Teva-ESO-000343		Authenticity
1416	ANDA No. 78-003, Section VI, In Vivo Studies.	11/23/2005	Teva-ESO-000469	Teva-ESO-000521		Authenticity
1417	ANDA No. 78-003, Section VI, Formulation Data.	11/23/2005	Teva-ESO-000634	Teva-ESO-000634		
1418	ANDA No. 78-003, Section VII, Components and Compositions Statements.	11/23/2005	Teva-ESO-000635	Teva-ESO-000640		
1419	ANDA No. 78-003, Section VIII, 1, Raw Material Controls, Active Ingredient.	11/23/2005	Teva-ESO-000643	Teva-ESO-000705		Authenticity
1420	ANDA No. 78-003, Section IX, Description of Manufacturing Facility.	11/23/2005	Teva-ESO-000895	Teva-ESO-000911		
1421	Letter from FDA to Ivax Pharmaceuticals	01/23/2006	Teva-ESO-003508	Teva-ESO-003509		
1422	Letter from FDA to Ivax Pharmaceuticals	04/12/2006	Teva-ESO-003598	Teva-ESO-003601		
1423	Letter from FDA to Ivax Pharmaceuticals	05/05/2006	Teva-ESO-007012	Teva-ESO-007017		
1424	Letter from FDA to Ivax Pharmaceuticals	10/03/2006	Teva-ESO-076646	Teva-ESO-076648		Authenticity
1425	ANDA No. 78-003, Amendment.	11/13/2006	Teva-ESO-011011	Teva-ESO-011071		
1426	Letter from FDA to Ivax Pharmaceuticals	01/10/2007	Teva-ESO-146887	Teva-ESO-146890		

Reference	Description	Date	Ref Doc	End Date	Additional Info	REVISED OR LOST
1427	Letter from FDA to Ivax Pharmaceuticals	05/11/2007	Teva-ESO-011073		Teva-ESO-011076	
1428	ANDA No. 78-003, Amendment.	03/04/2008	Teva-ESO-011085		Teva-ESO-012552	Authenticity
1429	ANDA No. 78-003, Amendment.	05/29/2008	Teva-ESO-012554		Teva-ESO-012558	
1430	Submission letter.					
1430	Letter from FDA to Ivax Pharmaceuticals	08/05/2008	Teva-ESO-019405		Teva-ESO-019408	
1431	ANDA No. 78-003, Amendment.	08/25/2008	Teva-ESO-110770		Teva-ESO-110775	Authenticity
1432	ANDA No. 78-003, Amendment.	09/12/2008	Teva-ESO-016546		Teva-ESO-016684	Authenticity
1433	Letter from FDA to Ivax Pharmaceuticals	11/25/2008	Teva-ESO-016538		Teva-ESO-016545	
1434	ANDA No. 78-003, Amendment.	09/22/2009	Teva-ESO-019418		Teva-ESO-019419	
1435	ANDA No. 78-003, Amendment.	08/19/2011	Teva-ESO-019420		Teva-ESO-019428	
1436	ANDA No. 78-003, Amendment.	08/19/2011	Teva-ESO-021509		Teva-ESO-021516	
1437	ANDA No. 78-003, Amendment.	08/19/2011	Teva-ESO-021608		Teva-ESO-021628	
1438	Module 3.2.P.4. Batch Analysis.	08/19/2011	Teva-ESO-021631		Teva-ESO-021632	
1438	ANDA No. 78-003, Amendment.					
1438	Module 3.2.S.5. Justifications of Specifications, Polymorphism Statement.					
1439	Letter from FDA to Ivax Pharmaceuticals	03/07/2012	Teva-ESO-019429		Teva-ESO-019432	
1440	Letter from FDA to Teva	04/03/2012	Teva-ESO-019433		Teva-ESO-019436	
1441	Letter from FDA to Teva	09/26/2012	Teva-ESO-019445		Teva-ESO-019450	
1442	ANDA No. 78-003, Amendment.	04/25/2013	Teva-ESO-146879		Teva-ESO-146886	
1443	Letter					Incomplete
1443	DMF No. 18821, Submission letter.	09/28/2005	DRLMDL196511		DRLMDL196511	
1444	DMF No. 18821, Modules 3.2.S.1 through 3.2.S.2.	09/28/2005	DRLMDL196521		DRLMDL196573	
1446	DMF No. 18821, Module 3.2.S.2.	09/28/2005	AZ-NX-MDL-01258617		AZ-NX-MDL-01258617	
1446	Description of Manufacturing Process and Process Controls.					
1448	DMF No. 18821, Module 3.2.M.4.	09/28/2005	DRLMDL197265		DRLMDL197265	
1449	DMF No. 18821, Amendment, Draft.	05/29/2005	Teva-ESO-048078		Teva-ESO-048078	Hearsay
1450	ANDA No. 78-279, Submission letter.	04/25/2006	DRLMDL174559		DRLMDL174561	
1451	ANDA No. 78-279, Original Submission.	04/25/2006	NEX-RBX 3417386		NEX-RBX 3421212	
1452	ANDA No. 78-279, Section VII, Components and Compositions Statements.	04/25/2006	DRLMDL000486		DRLMDL000503	
1454	ANDA No. 78-279, Section XV, Analytical Methods.	04/25/2006	NEX-RBX 3420400		NEX-RBX 3421029	
1455	ANDA No. 78-279, Amendment.	08/13/2007	DRLMDL153698		DRLMDL153713	
1455	Letter.					
1456	ANDA No. 78-279, Amendment.	08/13/2007	DRLMDL153731		DRLMDL153740	
1456	Exhibit-3					
1458	ANDA No. 78-279, Amendment.	02/22/2008	DRLMDL006046		DRLMDL005097	
1461	DMF No. 19192, Table of contents and Section A, Address File.	02/21/2006	NEX-RBX 3421215		NEX-RBX 3421223	Hearsay; incomplete
1462	DMF No. 19192, Section F.1, Drug Description.	02/21/2006	NEX-RBX 3421277		NEX-RBX 3421304	Hearsay; incomplete
1463	DMF No. 19192, Section F.3.1, Process Description.	02/21/2006	NEX-RBX 3421348		NEX-RBX 3421370	Hearsay; incomplete
1463	Process Description.					

Reference	Description	Date	Ref Doc	Ref Doc	Additional Ref Doc	REVIEWED/DATE
1464	DMF No. 19192, Section G.1, Raw Materials, Specifications and Test Methods, Omeprazole USP.	02/21/2006	NEX-RBX 3421377	NEX-RBX 3422406		Authenticity; Hearsay; Incomplete
1465	DMF No. 19192, Section G.3, Spectral Data of Reference Standard/Working Standard.	02/21/2006	NEX-RBX 3421601	NEX-RBX 3421605		Hearsay; Incomplete
1466	DMF No. 19192, Section G.2, Drug Substance; Certificate of Analysis.	02/21/2006	NEX-RBX 3421762	NEX-RBX 3421768		Hearsay; Incomplete
1467	DMF No. 19192, Volume 3 of 3.	02/21/2006	NEX-RBX 3422246	NEX-RBX 34222491		
1468	DMF No. 19192, Amendment.	01/28/2010	DRLMDL 152010	DRLMDL 152358		
1469	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153010	DRLMDL 163522		
	Submission Letter and Volume 1.					
1470	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153078	DRLMDL 163100		
1471	Section F.1.1, General Properties.	08/19/2010	DRLMDL 153101	DRLMDL 163127		
	Section F.1.2, Structural Elucidation Report of Esomeprazole Magnesium (Amorphous Form).					
1472	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153131	DRLMDL 163152		
	Section F.1.3, Process Description.					
1473	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153261	DRLMDL 163285		
	Section G.4, Intermediates; Specifications and Test Methods.					
1474	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153388	DRLMDL 163395		
	Section G.7.2, Drug Substance; Certificate of Analysis.					
1475	DMF No. 19192, Amendment.	08/19/2010	DRLMDL 153538	DRLMDL 163555		
	Annexure-1, Executed Batch Production Records.					
1476	DMF No. 19192, Amendment.	04/26/2012	DRLMDL 261755	DRLMDL 261755		
	Submission letter.					
1477	DMF No. 19192, Amendment.	04/26/2012	DRLMDL 261427	DRLMDL 261700		
1479	DMF No. 19192, Annual Report.	04/05/2013	DRLMDL 219738	DRLMDL 219747		
1480	ANDA No. 77-30; Original Submission.	08/04/2005	RAN-ESM009258	RAN-ESM00917		Missing Image
1481	ANDA No. 75-0103; Original Submission.	11/23/2005	Teva-ESO-000074	Teva-ESO-003507		
1483	ANDA No. 78-279; Sections I-V.	04/25/2006	DRLMDL 000053	DRLMDL 000081		
1484	Annexures I-VI.	08/17/2007	RAN-ESM009477	RAN-ESM009825		
1485	DMF No. 18559, Amendment.	08/17/2007	RAN-ESM009864	RAN-ESM009879		
	Annexures VII-XI.					
1486	ANDA No. 78-279; Section F.3, Final product packaging and labeling.	08/19/2011	Teva-ESO-021114	Teva-ESO-021632		
1487	DMF No. 19192, Amendment.	02/21/2006	NEX-RBX 3421371	NEX-RBX 3421375		
	Annexure-2.					
1488	Product Grid 2005.	08/19/2010	DRLMDL 163766	DRLMDL 163855		
1502	Nexium Strategic Plan	05/01/2000	NEX-RBX 3508252	NEX-RBX 3508269		
1515	Email from E. Mittleberg to M. Kapcha	10/03/2005	Teva-ESO-007361	Teva-ESO-007361		
1518	Ranbaxy spreadsheet; FTF Forecast.	11/11/2005	RAN-ESM0192913	RAN-ESM0192941		
1520	Ranbaxy spreadsheet; Master Product Grid 2005.	12/05/2005	RAN-ESM0195737	RAN-ESM0195786		
1522	Ranbaxy spreadsheet; Esomeprazole Magnesium Capsules - Market Forecasts and RPI Sales.	06/20/2006	RAN-ESM0194086	RAN-ESM0194105		
						Incomplete; Relevance; Hearsay

Plaintiff's Case No.	Description	Date	Basis for Belief or Knowledge	Additional Basis for Belief or Knowledge	Revised Objection
1523	E-mail from E. Stewart to T. Crew with attached Cipia Products Forecast spreadsheet	10/03/2006	Teva-ESO-084517	Teva-ESO-084517	Teva-ESO-084518.000001 - Teva-ESO-084518.000004
1525	AstraZeneca presentation. Building a Megabrand: Nexiumâ, c, Preparing for Success in the U.S.	02/26/2007	NEX-RBX 0593902	NEX-RBX 0593968	Authenticity; Incomplete
1526	Ranbaxy spreadsheet: Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	04/06/2007	RAN-ESM0186098	RAN-ESM0186117	Incomplete; Relevance; Hearsay
1527	Ranbaxy spreadsheet: Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	04/30/2007	RAN-ESM0134201	RAN-ESM0134220	Incomplete; Relevance; Hearsay
1528	E-mail from J. Tolisio to J. Bindra with attached Authorized Generic Partnership, Merck - Ranbaxy Slides Presentation - Genesis Overview	05/16/2007	RAN-ESM0233581	RAN-ESM0233589	Incomplete; Relevance; Hearsay
1531	E-mail from S. Rothwell to S. Barker with attached Genesis Overview presentation	10/29/2007	AZ-NX-MDL-01243707	AZ-NX-MDL-0124713	Foundation; Hearsay; Relevance
1532	E-mail from R. Barker to multiple recipients with attached Potential NEXIUMâ AG Overview presentation	10/29/2007	NEX-RBX 3514270	NEX-RBX 3514277	Cumulative; Hearsay
1534	E-mail from R. Barker to multiple recipients with attached Potential NEXIUMâ AG Overview presentation	11/09/2007	NEX-RBX 3456118	NEX-RBX 3456128	Hearsay
1535	AstraZeneca presentation. Potential NEXIUMâ AG Overview.	11/12/2007	NEX-RBX 3514135	NEX-RBX 3514144	Hearsay; Unfairly Prejudicial
1536	AstraZeneca presentation. 2008 Price Considerations.	12/07/2007	AZ-NX-MDL-00915610.000001	AZ-NX-MDL-00915610.000016	Hearsay
1539	Ranbaxy spreadsheet: Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	02/01/2008	RAN-ESM0054644	RAN-ESM0054659	Hearsay; Unfairly Prejudicial
1540	Form 20-F, Teva Pharmaceutical Industries Limited, for the fiscal year ended December 31, 2007	02/28/2008	Teva-ESO-024055	Teva-ESO-024224	Incomplete
1541	AstraZeneca presentation. Strategic Options for Nexium OTC.	02/29/2008	NEX-RBX 3426588	NEX-RBX 3426598	Relevance
1542	AstraZeneca spreadsheet. Assumptions in Nexium P&L. Moving from Base Case ABU submission (9/13/07) to the generic entry in April 1, 2008.	02/29/2008	NEX-RBX 3457467	NEX-RBX 3457473	
1543	AstraZeneca spreadsheet. Assumptions in Nexium P&L. Moving from Base Case Budget (1/08) and ABU (10/07) submission to the generic entry in April 1, 2008.	03/05/2008	NEX-RBX 3432365	NEX-RBX 3432373	Hearsay
1544	AstraZeneca spreadsheet. Assumptions in Nexium P&L. Moving from February 2008 MLF submission to the generic entry in April 1, 2008.	03/05/2008	NEX-RBX 3432383	NEX-RBX 3432391	Hearsay
1545	AstraZeneca spreadsheet. Assumptions in Nexium P&L. Moving from February 2008 MLF submission to the generic entry in April 1, 2008.	03/07/2008	NEX-RBX 3432374	NEX-RBX 3432382	Hearsay
1548	E-mail from R. Barker to J. Brazco	03/26/2008	NEX-RBX 3514303	NEX-RBX 3514303	Hearsay
1552	E-mail from S. Santacroce to multiple recipients	04/21/2008	RAN-ESM0092131	RAN-ESM0092138	Hearsay; Incomplete
					Authenticity; Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial; Relevance

PL#	Description	Date	File#	Doc#	Additional Doc#	Entered Doc#	REvised Doc#
1553	E-mail from M. McCourt to M. B - Working Session, Scenario Review and Discussion.	04/26/2008	NEX-RBX 3505839			NEX-RBX 3505850	
1554	AstraZeneca memo. Minutes and Action Items from AZ/Ohm Meeting, May 6, 2008.	05/12/2008	NEX-RBX 3513641			NEX-RBX 3513643	Hearsay
1557	Ranbaxy spreadsheet. Esomeprazole DR Cap Pellets.	07/03/2008	RAN-ESM0188739			RAN-ESM0188762	Double Hearsay; Hearsay
1558	E-mail from S. Pandit to J. Todisco with attached Esomeprazole Forecast spreadsheet	07/03/2008	RAN-ESM0202721			RAN-ESM0202727	Incomplete; Relevance; Hearsay
1560	E-mail from Venkatachalam to Panji re: FTF Products	07/13/2009	RAN-ESM 0488474			RAN-ESM 0488478	Relevance; Hearsay
1561	AstraZeneca spreadsheet. Nexium Franchise Pricing (AMP & WAC) By NDC, Jan. 2001 - July 2008.	04/13/2009	NEX-RBX 3524937			NEX-RBX 3524941	Foundation; Relevance
1563	E-mail from J. Todisco to Venkatachalam w/ attached Paonta Priority List spreadsheet and Paonta Sahib Applications spreadsheet	04/21/2009	RAN-ESM 0470162			RAN-ESM 0470167	Authenticity; Hearsay
1564	Teva spreadsheet. Deal Esomeprazole DR Caps.	06/05/2009	Teva-ESO-0081242.000001			Teva-ESO-081242.0000017	Authenticity; Hearsay
1566	Ranbaxy spreadsheet. Esomeprazole Forecast 8-28-09.	08/28/2009	RAN-ESM 0462657			RAN-ESM 0462655	Incomplete; Relevance; Hearsay
1567	AstraZeneca presentation. Genesis Update.	09/28/2009	AZ-NX-MDL-00946916.000001			AZ-NX-MDL-00946916.000003	Double Hearsay; Hearsay; Misleading
1568	Declaration of Joseph Todisco in Support of Ranbaxy Laboratories Limited's and Ranbaxy Inc.'s Motion to Intervene and Motion to Dismiss, Dkt. 21, No. 09-cv-00485 (M.D.N.C.)	10/08/2009	Dkt. 21, No. 09-cv-00485 (M.D.N.C.)				Hearsay; Relevance; Misleading
1569	Teva spreadsheet. Potential Competition Exclusivity Forfeiture.	11/16/2009	Teva-ESO-047045			Teva-ESO-047045	Authenticity; Foundation, Hearsay
1572	E-mail from ERI Chandra Sekar to V. Bhaskar.	11/04/2010	DRIMDL 222897			DRIMDL 222897	Double Hearsay; Foundation; Hearsay
1573	DRU spreadsheet. Esomeprazole Mg BC 04.01.11.	01/04/2011	DRUMLD 240924			DRUMLD 240946	Unfairly Prejudicial
1574	E-mail from S. Shubhaya to S. Rao with attached esomeprazole model spreadsheet	01/06/2011	DRUMLD 179341			DRUMLD 179348	Authenticity; Hearsay
1575	Dr. Reddy's Labs Pre-Draft Brief "One Page" (Confidential) - Esomeprazole Draft LITs.	01/10/2011	DRUMLD 179353			DRUMLD 179363	
1576	Dr. Reddy's Laboratories Pre-Draft Brief "One Page" (Confidential) - Esomeprazole	01/10/2011	DRUMLD 219178			DRUMLD 219189	Hearsay
1577	AstraZeneca presentation. Brand LITs.	06/20/2011	AZ-NX-MDL-00942410.000001			AZ-NX-MDL-00942410.0000014	Hearsay; Double Hearsay; Unfairly Prejudicial; Improper Exhibit (deposition transcript); Relevance
1578	Transcript of investigational hearing, Joseph Todisco, FTC File No. 0810171	09/14/2011	RAN-ESM 0631843			RAN-ESM 0631859	Authenticity; Double Hearsay; Hearsay; Improper Exhibit (deposition transcript); Unfairly Prejudicial
1579	Transcript of investigational hearing, Venkatachalam Krishnan, FTC File No. 0810171	10/20/2011	RAN-ESM 0631870			RAN-ESM 0631882	

Exhibit	Description	Date	Begin Doc#	End Doc#	Additional Notes	REVISED OBJECTION
1580	E-mail from M. Dawson to C. Proctor and G. Rowles with attached 2011 Q2RBU USL Pre-Read, Key Brand Summary presentation	04/26/2012	AZ-NX-MDL-00847315	AZ-NX-MDL-00847316	AZ-NX-MDL-00847317.000/001 - AZ-NX-MDL-00847317.000/015	Hearsay
1581	E-mail from R. Polyboisky to M. Diegues and J. Valentine with attached Nestum erosion scenarios summary spreadsheet and generic erosion analysis presentation	05/30/2012	AZ-NX-MDL-00906234	AZ-NX-MDL-00906234	AZ-NX-MDL-00906235.000/001 - AZ-NX-MDL-00906235.000/02; AZ-NX-MDL-00906236.000/001 - AZ-NX-MDL-00906236.000/09	Hearsay
1582	AstraZeneca presentation, Express Scripts & Medco, Nestum.	06/25/2012	AZ-NX-MDL-00895722.000001	AZ-NX-MDL-00895722.000018	AZ-NX-MDL-00895722.000018	Hearsay
1583	E-mail from S. Nichols to multiple recipients with attached NEXUMI 2013 - 2014, Preliminary Strategy presentation	07/31/2012	AZ-NX-MDL-008959291	AZ-NX-MDL-008959291	AZ-NX-MDL-008959292.000001 - AZ-NX-MDL-008959292.000010	Hearsay
1584	DRL spreadsheet, Costing Details - Esomeprazole Magnesium Delayed Release Capsules.	12/27/2012	DRLMDL 337541	DRLMDL 337592		
1585	AstraZeneca spreadsheet, Nestum Capsule Product Contribution [2004 - 1H2013]	07/30/2013	AZ-NX-MDL-01231531	AZ-NX-MDL-01231531		Foundation; Relevance
1587	AstraZeneca presentation, Nestum, the first PPI developed as an isomer, Evolution beyond all PPIs.	undated	NEK-RBX 5676023	NEK-RBX 0576122		Hearsay; Incomplete
1590	AstraZeneca presentation, Company Plan B, Financial Impact & Options Considered.	undated	NEK-RBX 3432402	NEK-RBX 3432407		Hearsay; Unfairly Prejudicial
1591	Teva spreadsheet: Esomeprazole Tablets Summary.	06/05/2009	Teva-ESO-065243	Teva-ESO-065243		Incomplete; Authenticity; Foundation; Hearsay
1592	IMS Consulting report to PhRMA, Assessment of Authorized Generics in the U.S.	03/01/2006	[no dates]			Authenticity; Hearsay
1593	Federal Trade Commission report, Authorized Generic Drugs: Short-Term Effects and Long-Term Impact.	08/01/2011	[no dates]			Authenticity; Double Hearsay; Hearsay; Unfairly Prejudicial
1594	M. Darby and E. Karmi, "Free Competition and the Optimal Amount of Fraud," <i>Journal of Law and Economics</i> , 16(1), 1973, pp. 67-88.	01/01/1973	[no dates]			Authenticity; Hearsay; Unfairly Prejudicial
1595	P. Nelson, "Advertising as Information," <i>The Journal of Political Economy</i> , 82(4), 1974, pp. 729-754.	01/01/1974	[no dates]			Authenticity; Hearsay; Relevance
1596	A. Friedlaender, C. Winston, and K. Wang, "Costs, Technology, and Productivity in the U.S. Automobile Industry," <i>The Bell Journal of Economics</i> , 14(1), 1983, pp. 1-20.	01/01/1983	[no dates]			Authenticity; Hearsay; Relevance
1597	C. Winston and F. Mannerling, "Consumer Demand for Automobile Safety," <i>The American Economic Review</i> , 74(2), 1984, pp. 316-319.	01/01/1984	[no dates]			Authenticity; Hearsay; Relevance
1598	United States Congress, Office of Technology Assessment, "Pharmaceutical R&D: Costs, Risks and Rewards," Washington D.C., 1993.	01/01/1993	[no dates]			Authenticity; Hearsay; Relevance; Unfairly Prejudicial

Exhibit	Description	Date	BerDoc	EndDoc	Additional Bates	REVISED DOCUMENT
1600	S. Berry, J. Levinsohn and A. Pakes, "Automobile Prices in Market Equilibrium," <i>Econometrica</i> , 63(4), 1995, pp. 841-890.	01/01/1995	[no bates]			Authenticity; Hearsay; Relevance
1601	S.F. Ellison, I. Cockburn, Z. Griliches, and J. Hausman, "Characteristics of Demand for Pharmaceutical Cephalosporins," <i>RAND Journal of Economics</i> , 28(3), 1997, pp. 426-446.	01/01/1997	[no bates]			Authenticity; Hearsay; Relevance
1602	Department of Justice and Federal Trade Commission, Horizontal Merger Guidelines, Apr. 2 1992, Revised Apr. 8, 1997.	04/08/1997	[no bates]			Authenticity; Hearsay; Relevance
1604	D. Balto, "Pharmaceutical Patent Settlements: The Antitrust Risks," <i>Food and Drug Law Journal</i> , 55, 2000, pp. 321-341 at 324-325.	01/01/2000	[no bates]			Authenticity; Hearsay; Unfairly Prejudicial
1605	D. Suh, W. Manning, S. Schondelmeier, and R. Hadall, "Effect of Multiple-Source Entry on Price Competition After Patent Expiration in the Pharmaceutical Industry," <i>Health Services Research</i> , 35(2), 2000, pp. 525-547	01/01/2000	[no bates]			Authenticity; Hearsay; Unfairly Prejudicial
1606	Federal Trade Commission News Release, "FTC Charges Drug Manufacturers with Stifling Competition in Two Prescription Drug Markets," March 16, 2000.	03/16/2000	[no bates]			Authenticity; Double Hearsay; Hearsay
1607	W. Emmons, "Credence Goods Monopolists," <i>International Journal of Industrial Organization</i> , 18(3-4), 2000, pp. 375-389.	01/01/2001	[no bates]			Authenticity; Hearsay; Relevance
1608	E. Berndt, A. Bhattacharya, D. Mishol, A. Arcelius and T. Lasky, "An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts," <i>The Journal of Mental Health Policy and Economics</i> , 5(1), 2002, pp. 3-19.	01/01/2002	[no bates]			Authenticity; Hearsay
1609	M. Rosenthal, E. Berndt, J. Donohue, R. Frank and A. Epstein, "Promotion of Prescription Drugs to Consumers," <i>New England Journal of Medicine</i> , 346(7), February 2002, pp. 498-505.	02/01/2002	[no bates]			Authenticity; Hearsay; Relevance
1611	U. Dulbeck and R. Kerschbamer, "On Doctors, Mechanics, and Computer Specialists: The Economics of Credence Goods," <i>Journal of Economic Literature</i> , 44(1), 2006, pp. 5-42.	01/01/2006	[no bates]			Authenticity; Hearsay; Relevance

Exhibit	Description	Date	By Doc	Additional Notes	Reviewed by
1612	B. Landen, M. Rosenthal, S. Normand, C. Spertell; A. Lessler, H. Underwood and J. Newhouse, "Incentive Formularies and Changes in Prescription Drug Spending," <i>The American Journal of Managed Care</i> , 13(6), June 2007, pp. 360-9.	06/01/2007	[no dates]		Authenticity; Hearsay; Relevance
1613	R. Larrier, and C. Nelson, CRA International, "Market Definition in Cases Involving Branded and Generic Pharmaceuticals," TBA Section of Antitrust Law, Economic Committee Newsletter, 7(2), Fall 2007.	09/01/2007	[no dates]		Authenticity; Hearsay
1614	IMS, The Uniform System of Classification (USC), Revised March 2008, <a href="https://www.imshealth.com/deployables/ims/global/content/insights/Health%20Services%20Research%20Network%20USC_Classification_Process_2011.pdf">https://www.imshealth.com/deployables/ims/global/content/insights/Health%20Services%20Research%20Network%20USC_Classification_Process_2011.pdf</a> .	03/01/2008	[no dates]		Authenticity; Hearsay
1615	L. Kaplow, "Why [Even] Define Markets?" <i>Harvard Law Review</i> , 124(437), 2010, p. 512.	01/01/2010	[no dates]		Authenticity; Hearsay
1617	Aitken, M.L. et al., "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," TBER Working Paper No. 19487, October 2013.	10/01/2013	[no dates]		Authenticity; Hearsay
1618	FDA, "Abbreviated New Drug Application (ANDA); Generic" <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HmNewDrugs/ApprovedandApproved/ApprovalsApplications/abbreviatedNewDrug/applications/ANDA/Default.htm">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HmNewDrugs/ApprovedandApproved/ApprovalsApplications/abbreviatedNewDrug/applications/ANDA/Default.htm</a> .	undated	[no dates]		Authenticity; Hearsay
1619	PDRHealth, Physician Desk Reference ( <a href="http://www.pdrhealth.com/drugs/medium">http://www.pdrhealth.com/drugs/medium</a> ).	undated	[no dates]		Authenticity; Hearsay
1621	FDA, Guidance for Industry, SUPAC-MR: Modified Release Solid Oral Dosage Forms, Rockville (MD): FDA; 1997 Sep.	09/01/1997	[no dates]		Authenticity; Hearsay; Incomplete
1622	Development Agreement between Ixax and Cipla	12/19/2002	Teva-ESO-056360	Teva-ESO-066373	Authenticity; Hearsay; Relevance
1623	Supply Agreement between Ixax and Cipla	07/15/2003	Teva-ESO-050363	Teva-ESO-030383	Authenticity; Hearsay
1627	2004-2010 Projected Launch Dates for US, Change Report.	01/31/2005	Teva-ESO-146887	Teva-ESO-146967	Authenticity; Hearsay
1630	E-mail from E. Mittelberg to M. Kopcha	10/03/2005	Teva-ESO-007931	Teva-ESO-007931	Hearsay
1633	E-mail from B. Malik to O. Seithi, Venkatachalam K. and G. Mehrotra with attached ANDA filings spreadsheet	12/19/2005	RAN-ESM0096778	RAN-ESM0096790	Relevance

Exhibit	Description	Date	BE Doc#	Additional Bates	REVISER/OBJECTION
1636	Inspectional Observations Form FDA 483. Dkt. 1-4, No. 08-cv-01764 (D. Md.)	02/25/2006	Dkt. 1-4, 08-cv-01764 (D. Md.)		Authenticity; Hearsay; Incomplete
1638	Form 20-F, Teva Pharmaceutical Industries Limited, for the fiscal year ended December 31, 2005	03/17/2006	[no bates]		Authenticity
1639	E-mail from S. Jille to J. Pott with attached letter	04/14/2006	Teva-ESO-023579	Teva-ESO-023581	Authenticity; Hearsay; Incomplete
1641	E-mail from R. Shetty to S. Drosatou	04/24/2006	Teva-ESO-007148	Teva-ESO-007148	Authenticity; Hearsay
1642	E-mail from R. Shetty to P. Jaworski	04/26/2006	Teva-ESO-007294	Teva-ESO-007294	Hearsay
1643	E-mail from J. Sjölin to B. Hobart	04/26/2006	Teva-ESO-082576	Teva-ESO-082576	Authenticity; Incomplete
1644	E-mail from R. Shetty to S. Drosatou	04/27/2006	Teva-ESO-007154	Teva-ESO-007155	Authenticity; Hearsay
1646	E-mail from R. Shetty to Z. Titi and response from S. Drosatou	05/03/2006	Teva-ESO-007160	Teva-ESO-007162	Hearsay
1647	E-mail from R. Shetty to S. Drosatou	05/04/2006	Teva-ESO-007163	Teva-ESO-007165	Hearsay
1648	E-mail from S. Drosatou to P. Jaworski	05/29/2006	Teva-ESO-076788	Teva-ESO-076790	Relevance; prejudice; Hearsay
1649	E-mail from J. King to S. Drosatou with attached Esomeprazole DR Caps forecast	05/30/2006	Teva-ESO-022852	Teva-ESO-022853	Teva-ESO-022856
1650	E-mail from D. Stark to S. Julie	05/31/2006	Teva-ESO-033557	Teva-ESO-033559	Relevance; Hearsay
1651	Warning Letter 320-06-03 from FDA to Ranbaxy, Dkt. 1-5, No. 08-cv-01764 (D. Md. 2008)	06/15/2006	Okt. 1-5, No. 08-cv-01764 (D. Md. 2008)		Misleading
1652	E-mail from T. Crew to E. Shohet with attached Cipla Summary presentation and Cipla Product Summary spreadsheet	09/07/2006	Teva-ESO-084754	Teva-ESO-084760	Authenticity; Incomplete; Relevance; Hearsay
1654	E-mail from S. Drosatou to P. Jaworski and M. Zamore with attached Iwax pipeline spreadsheet with attached Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06	09/25/2006	Teva-ESO-016784	Teva-ESO-016785	
1655	E-mail from M. Grewal to R. Lakeskie with attached Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06 with attached Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06 Mehratra with attached October '07 monthly report for the US AstraZeneca Competitive Price Sheet	09/21/2006	RAN-ESM0198423	RAN-ESM0198443	Authenticity; Relevance
1657	E-mail from Venkatachalam K. to G. Mehratra with attached Region IVA Budget 2007 presentation Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06 recipients with attached Region IVA Budget 2007 presentation	11/07/2006	RAN-ESM0094360	RAN-ESM0094375	Authenticity; Relevance
1658	E-mail from G. Mehratra to multiple recipients with attached Region IVA Budget 2007 presentation Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06	01/05/2007	NEX-RBX 3431815	NEX-RBX 3431818	Hearsay
1659	E-mail from S. Drosatou to M. Cavanaugh with attached Cipla New Product Launches - Status Update	01/05/2007	RAN-ESM0172229	RAN-ESM0172395	Authenticity; Hearsay; Unfairly Prejudicial
1661	E-mail from S. Drosatou to M. Cavanaugh with attached Cipla New Product Launches - Status Update attached Esomeprazole DR Capsules document	02/26/2007	RAN-ESM0173586	RAN-ESM0173604	Incomplete; Relevance; Hearsay
1662	Teva spreadsheet, Forecast for Esomeprazole Magnesium DR 40 mg.	02/26/2007	Teva-ESO-135147.000001	Teva-ESO-135147.000005	Authenticity; Incomplete; Foundation, Hearsay
1663	E-mail from S. Drosatou to M. Cavanaugh with attached Cipla New Product Launches - Status Update	03/28/2007	Teva-ESO-087735	Teva-ESO-087737	Authenticity; Hearsay
1664	E-mail from Z. Titi to S. Drosatou with attached Esomeprazole DR Capsules document	04/10/2007	Teva-ESO-075757	Teva-ESO-075759	Authenticity; Hearsay
1665	Letter from FDA to Ranbaxy approving ANDA No. 76-445 [Pravastatin Sodium Tablets]	04/23/2007	[no bates]		Authenticity; Relevance; Unfairly Prejudicial